 
PROTOCOL  CTAP101 -CL-2014  
Study Title:  A Randomized , Double -Blind Placebo -Controlled Study to E valuate the 
Safety  and  Efficacy of Rayaldee ( calcifediol ) Extended -relea se Capsules 
to Treat Symptomatic Patients Infected  with SARS -CoV -2 (REsCue) 
Study  Number:  CTAP101 -CL-2014  (Ver. 8.0, 12 November  2021) 
Short Title:  Safety and  Efficacy of Rayaldee  for Treating Mild to Moderate COVID -
19  
Study Phase:  [ADDRESS_249823] Name:  [CONTACT_209102]® (calcifediol) Extended -release Capsules  (30 mcg)  
Investigator :  
Sponsor:  
OPKO  Pharmaceuticals, LLC  
[ADDRESS_249824]:  
Joel Melnick, MD  
 
  
 
[ADDRESS_249825]  
Miami, FL [ZIP_CODE]  
  
 
   
 
  
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study will be conducted in compliance with the protocol, US Code of Federal 
Regulations (CFR) applicable to clinical studies, principles of International Council on 
Harmonization ( ICH) Good Clinical Practice  (GCP) , the Declaration of Helsinki, and all 
applicable regulatory requirements.  
Confidentiality Statement  
This protocol is the confidential information of  OPKO Pharmaceuticals, LLC and is intended solely for the guidance of 
the clinical investigation.  This protocol may not be disclosed to parties not associated with the clinical investigation or 
used for any purpose without the prior  written consent of OPKO Pharmaceuticals, LLC    CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249826] OF ABBREVIATION S AND DEFINITION OF TERMS  ................................ .......15 
1 INTRODUCTION  ................................ ................................ ................................ .......... 17 
1.1 Vitamin D Insufficiency  ................................ ................................ ............................. 17 
1.2 Vitamin D and Viral Infections  ................................ ................................ ................ 17 
1.3 Vitamin D and Cathelicidin Gene  ................................ ................................ ............ 18 
1.4 Preclinical Experience  ................................ ................................ ............................... 19 
1.5 Previous Clinical Experience  ................................ ................................ .................... 19 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ..21 
2.1 Study Obje ctives ................................ ................................ ................................ ......... 21 
2.1.1  Primary Objectives  ................................ ................................ .............................. 21 
2.1.2  Estimand  ................................ ................................ ................................ ............... 21 
2.1.3  Secondary Ob jectives:  ................................ ................................ ......................... 21 
  
3 INVESTIGATIONAL PLAN  ................................ ................................ ........................ 23 
3.1 Overall Study Design  ................................ ................................ ................................ .23 
3.2 Rationale for Study Design and Control Group  ................................ ..................... 23 
3.3 Evaluations  ................................ ................................ ................................ ................. 24 
3.4 Study Endpoints  ................................ ................................ ................................ ......... 24 
3.4.1  Primary Efficacy Endpoints ................................ ................................ ................ 24 
3.4.2  Secondary Efficacy Endpoints  ................................ ................................ ............ 25 
  
3.4.4  Primary Safety Endpoints  ................................ ................................ ................... 26 
3.5 Study Duration  ................................ ................................ ................................ ........... 26 
4 STUDY POPULATION SEL ECTION  ................................ ................................ ......... 27 
4.1 Study Population  ................................ ................................ ................................ ........ 27 
4.2 Inclusio n Criteria  ................................ ................................ ................................ .......27 
4.3 Exclusion Criteria  ................................ ................................ ................................ ......27 
5 STUDY TREATMENTS  ................................ ................................ ................................ 29 
5.1 Descriptio n of Rayaldee (CTAP101 Capsules)  ................................ ........................ [ADDRESS_249827] Activity Restrictions  ................................ ................................ ..................... 31 
5.7 Pregnancy and Contraception  ................................ ................................ .................. 31 
5.8 Treatment Compliance  ................................ ................................ .............................. 32 
5.9 Packaging and Labeling  ................................ ................................ ............................ 32 
5.10  Storage and Accountability  ................................ ................................ ....................... 32 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249828] (DSMB)  ................................ ................................ ..37 
6.7 Adverse Events Assessments  ................................ ................................ ..................... 38 
6.7.1  Definition  ................................ ................................ ................................ .............. 38 
6.7.2  Performing Adverse Events Assessments  ................................ .......................... 38 
6.7.3  AE Collection Period  ................................ ................................ ........................... 38 
6.7.4  Severity ................................ ................................ ................................ .................. 39 
6.7.5  Relationship  ................................ ................................ ................................ .......... 39 
6.7.6  Clinical Significance ................................ ................................ ............................. 40 
6.7.7  Serious Adverse Events  ................................ ................................ ....................... 40 
[IP_ADDRESS] Definition  ................................ ................................ ................................ ........ 40 
[IP_ADDRESS]  Expectedness  ................................ ................................ ................................ ...41 
[IP_ADDRESS]  Reporting Serious Adverse Events  ................................ ............................... 41 
6.7.8  Treatment -Emergent Adverse Events ................................ ................................ 42 
6.8 Concomitant Medication Assessments  ................................ ................................ .....42 
6.9 Removal of Subjects from the Study or Study Drug / Stoppi[INVESTIGATOR_2121]  ............. 42 
6.10  Appropriateness of Measurements  ................................ ................................ ........... 42 
7 STUDY ACTIVITIES  ................................ ................................ ................................ ....43 
7.1 Screening and Randomization (Visit 1/Day -3 to 1)  ................................ ................ 43 
7.1.1  Screening (Day -3 to 0)  ................................ ................................ ........................ 43 
7.1.2  Randomization and Initial Treatment (Day 1)  ................................ .................. 43 
7.2 Days 2 -6 ................................ ................................ ................................ ....................... 44 
7.3 Visit 2 (Day 7 ±  2) ................................ ................................ ................................ .......44 
7.4 Days 8 -13 ................................ ................................ ................................ ..................... 44 
7.5 Visit 3 (Day 14 ± 2)  ................................ ................................ ................................ .....45 
7.6 Days 15 -20 ................................ ................................ ................................ ................... 45 
7.7 Visit 4 (Day 21 ± 2)  ................................ ................................ ................................ .....45 
7.8 Days 22 -27 ................................ ................................ ................................ ................... 46 
7.9 Visit 5 (Day 2 8 + 2) (End of Treatment/Early Termination)  ................................ .46 
7.10  Days 29 -41 ................................ ................................ ................................ ................... 47 
7.11  Visit 6 (Day 42 ± 4 (Follow -up – Telephone Visit))  ................................ ................. 47 
8 QUALITY CONTROL AND ASSURANCE  ................................ ............................... 48 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ......49 
9.1 General Considerations  ................................ ................................ ............................. 49 
9.2 Missing Data  ................................ ................................ ................................ ............... 49 
9.3 Planned Data Safety Monitoring:  ................................ ................................ ............. 51 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249829] of Laboratory Tests  ................................ ................................ ................ 36 
Table 3  Adverse Event Relationship Criteria  ................................ ........................... 40 
 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 6 of 82 
 
Confidential    
   
 SYNOPSIS  
Sponsor :  
OPKO Pharmaceuticals , LLC  
Name [CONTACT_2756]:  
Rayaldee® (calcifediol) Extended -release Capsules  
[Extended -release calcifediol, coded as CTAP101 Capsules ] 
Name [CONTACT_3261]:   
Calcifediol, calcidiol, 25-hydroxyvitamin D [ADDRESS_249830] Products, Dose, and Mode of Administration :  
Rayaldee  (900 mcg) or matching place bo in a 900 mcg loading dose split into three equal doses 
of 300 mcg  each administered over three days ( on Days 1, 2 and 3 ) followed by  a maintenance 
dose of 60 mcg/day or matching placebo for 24 days by [CONTACT_149260]  (Days 4 -27). 
Study Title:  
A Randomized,  Double -Blind Placebo -Controlled Study to Evaluate the Sa fety and  Efficacy of 
Rayaldee (calcifediol) Extended -release Capsules to Treat Symptomatic Patients Infected with 
SARS -CoV -2 (REsCue) 
Study Phase:  2 
Rationale:  
Insufficient vitamin D (vitD) has been linked to a large number of pathologies including 
immune disorders and infectious diseases. VitD functions as a key host defense regulator 
against viral pathogens. High levels of vitD in the blood have been associated  with resistance to 
human immunodeficiency virus type 1 ( HIV1 ) infection.  Moreover, low levels of vitD have 
been associated with higher levels of immune activation and inflammation in HIV and other 
diseases. While the results of clinical trials studying v itD supplementation have differed, there 
are several well -designed , large meta -analyses that have supported vitD supplementation as 
safe and protective against acute respi[INVESTIGATOR_6014] , with those that were severely vitD 
deficient receiving the most benefit.  
The innate immune response in antigen -presenting cells (monocyte/macrophages and dendritic 
cells) is initiated and perpetuated by [CONTACT_209058] -associated molecular patterns (PAMP s) of the 
infecting virus interacting with pattern recognition receptors (eg, Toll -like receptors [TLR]). 
TLR activation leads to up -regulation of expression  of the intracellular vitD receptor (VDR) 
and CYP27B1 ( 25-hydroxyvitamin D [ 25D]-1α-hydroxylase); the latter event up -regulates 
local generation of the active vitD metabolite, 1,25 -dihydroxyvitamin D (1,25D). 1,25D can 
then engage the VDR in an intracrine mode, which, in turn, controls cathelicidin antimicrobial 
peptide (CAMP ) and interleukin 1ß (IL -1ß) gene expression, IL -1ß being a central initiator of 
the adaptive immune response.  
LL37 is a potent, central, endogenously synthesized antimicrobial protein in humans , the 
product of the CAMP  gene . Early in infection, LL37 is made principally by [CONTACT_209059], monocyte/macrophages and dendritic cells, initiators of the immune response to both 
bacterial and viral infections. Owing to serendipi[INVESTIGATOR_209034], a retrotransposon bearing a perfect vit D CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 7 of 82 
 
Confidential    
   
 response  element ( VDRE: AGGTCAXXXAGGTCA) was inserted  into the pro moter of the 
cathelicidin  gene in great apes and humans.  This ancient event made LL37 production 
dependent on transact ivation of CAMP  by [CONTACT_941] 1,25D -activated VDR.  
Extensive recent work shows that an insufficient supply of 25D to activated  VDR - and 
CYP27B1 -expressing human monocytes/macrophages  is associated with a decrease in CAMP  
expression . An insufficient level of 25D in human serum causes inadequate i) intracellular 
generation of 1,25D, ii) activation of the VDR, iii) transactivation of  the CAMP  gene and iv) 
production and release of LL37 to combat microbial invasion of the host. The end result is 
innate and subsequent adaptive immune deficiency.  
Raising serum total 25D to sufficiently high levels can resolve the immune -compromised stat e 
in the human host. Accomplishing this with vitD supplements is unreliable  and is difficult in 
obesity owing to the increased volume of distribution of the non -polar vitamin. In contrast, 
treatment with the more polar and extended -release calcifediol ( Rayaldee or CTAP101 
Capsules ) is reliable and, depending on the administered dose, can take as little as 9-12 hours.  
Treatment with CTAP101 Capsules  has been shown to be safe for administration to patients 
with stage 3 or 4 chronic kidney disease (CKD), as e videnced by [CONTACT_209060] (US) Food and 
Drug Administration (FDA) approval of the product in 2016 as Rayaldee® (calcifediol) 
Extended -release Capsules.   
Accumulating data suggest that hyperactive immune response to COVID -[ADDRESS_249831] the depletion and exhaustion of T 
cell populations. On the other hand, vitD is an immune -modulating agent and has  been 
implicated in the pathophysiology of autoimmune diseases, including systemic lupus 
erythematosus  and multiple sclerosis. Vit amin D  insufficiency (VDI) is a risk factor for 
multiple sclerosis and correlates with the disease severity. Thus,  
 appropriate treatment with 
Rayaldee may help to mitigate an overactive , adaptive  T- and B -lymphocyte immune system 
and ameliorate immune cell exhaustion.  
We propose a dou ble-blind randomized, placebo -controlled trial of extended -release calcifediol  
(commercially available as Rayaldee and coded herein as CTAP101 Capsules) in [ADDRESS_249832] positive  for 
severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV -2) via nas opharynx  swab reverse 
transcription polymerase chain reaction  (RT-PCR ) or any substitutable FDA -authorized 
diagnostic test .  The hypothesis is that the severity  and duration of the disease  will be a ttenuated 
with increase of serum 25D to levels of ≥50 ng/mL.  
Primary Objectives:  
The primary objectives of this study are to compare  the effects of Rayaldee ( CTAP101 
Capsules ) vs. placebo treatment in patients with mild to moderate COVID -19 on the:  
1) Attainment of serum total 25D levels at or above 50 ng/mL by [CONTACT_2006] 14; and,  
2) Severity  and duration of disease as evi denced by  [CONTACT_209061] -19 symptoms (trouble 
breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and 
shivering) using the FLU -PRO  Plus© questionnaire  as the data collection tool.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 8 of 82 
 
Confidential    
   
 Estimand:  
The study treatment estimand is the difference between [ADDRESS_249833] unresolved 
symptoms of mild to moderate COVID -19 in (a) the attainment of serum total 25D levels ≥50 
ng/mL as assessed at Day 14, and (b) the number of days to resolu tion of five symptoms 
(trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and 
shivering), as measured by [CONTACT_209062] -PRO Plus© questionnaire  with resolution defined as the 
first aggregate FLU -PRO Plus© symptom score of ≤5 which is maintained for a minimum of 
three consecutive days.  
Secondary Objectives:   
The secondary objectives are to compare  the effects of Rayaldee ( CTAP101 Capsules ) vs. 
placebo treatment on:   
1) The number of days to resolution of five symptoms (trouble breathing, chest congestion, 
dry or hacking cough, body aches and pains, and chills and shivering), as measured by 
[CONTACT_209062] -PRO Plus© questionnaire , with resolution defined as the first aggregate 
symptom score of ≤5 which is maintained for a minimum of thre e consecutive days, 
with no individual symptom score >1 ;  
2) Resolution, defined as the first score of ≤5 which is maintained for a minimum of three 
consecutive days (without subsequent relapse) , for the aggregate five COVID -19 
symptoms (trouble breathing, ch est congestion, dry or hacking cough, body aches and 
pains, and chills and shivering) and for each individual symptom, defined as a score of 0 
or 1, as measured by [CONTACT_209062] -PRO Plus© questionnaire  as of  Day 10;  
3) Incidence of emergency room /urgent care visits ; 
4) Incidence of oxygen saturation below 94%  (without supplemental oxygen) ; 
5) Incidence and duration of hospi[INVESTIGATOR_602];  
6) Incidence of r equirement for mechanical ventilation;  
7) Mortality rate  (as incidence) ; 
8) Severity and duration of COVID -19 illness as evidenced  by [CONTACT_102767] -of-life measures  
using the FLU -PRO  Plus© questionnaire ; and, 
9) Clinical cours e of COVID -19 as a function of serum 25D concentrations of <50 ng/mL, 
50 to 100 ng/mL and >10 0 ng/mL at Days 7, 14,  21 and 28 , defined as the proportion of 
subjects in e ach treatment group with a total sc ore of ≤5 for selected five COVID -19 
symptoms (tr ouble breathing, chest congestion, dry or hacking cough, body aches and 
pains, and chills and shivering) using the FLU -PRO Plus© questionna ire.  
 
 
 
 
 
 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 9 of 82 
 
Confidential    
   
  
 
 
 
  
 
 
 
Number of Subjects:  
Approximately 80 subjects will be randomized to  each of the Rayaldee ( CTAP101 Capsules ) 
and placebo treatment groups , for a total of 160 subjects.   
Safety Evaluations:    
The safety and tolerability of Rayaldee (CTAP101 Capsules) will be evaluated by [CONTACT_50914] ( AEs), physical examinations (PE), vital signs (VS), electrocardiograms (ECGs), 
hematology and clinical chemistries. Special attention will be given to changes in the following 
parameters : 
1) Serum total calcium (corrected for serum albumin);  
2) Serum phosphorus;  and, 
3) Estimated glomerular filtration rate ( eGFR ). 
Dose Reduction and Stoppi[INVESTIGATOR_1869]:  
Although hypercalcemia is unlikely given the extensive prior experience  with Rayaldee 
(CTAP101 Capsules) , any subject who exhibits a confirmed serum total calcium >10.5 and 
≤11.0 mg/dL (corrected for serum albumin) based on blood sample s obtained on Day s 7 and 14 
will reduce the daily maintenance dose by [CONTACT_89953] ( from 60 mcg to 30 mcg ) starting at Day 
21.  The d ose will similarly be reduced based on blood sample s obtained on  Days 7 and 14 if 
serum total 25D is confirmed to exceed 100 ng/mL, the maximum targeted  level in the FDA -
approved Package Insert for Rayaldee (se e APPENDIX  2.), starting at Day 21 .  
Subjects who exhibit confirmed serum total calcium >11.0 mg/dL (corrected for serum 
albumin)  based on blood samples obtained on Days 7, 14 and 21 will suspend dosing until  
normalization of serum calcium at which time (if applicable) dosing will be resumed at one 
capsule per day ( 30 mcg per day ).  Subjects will be requested to return to the clinic on the 
earliest possible day of their next scheduled visit (eg, Day 12 for the  Day 14 visit) for the 
confirmatory blood draw.  
Subjects who  develop severe (CTCAE ≥ 3)  abnormalities (low or high) of serum phosphorus, 
uric acid or plasma iPTH will be withdrawn from study drug treatment.  
Enrollment of subjects into the study will be paused if mortality in the treatment arm is ≥ 7% 
higher compared to the placebo arm until the Data Safety Monitoring Board ( DSMB ) makes an 
assessment about causality, and may resume once the DSMB deems it accep table to continue (if 
applicable).  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 11 of 82 
 
Confidential    
   
 symptoms at study drug initiation ( Day 1 ) to or below [ADDRESS_249834] day of 
achieving the aggregate ≤[ADDRESS_249835] two successive qualifying scores which span a minimum of three 
consecutive days. For cl arity, resolution will be considered as having been achieved if two 
successive aggregate scores of ≤[ADDRESS_249836] two days (but not more than 5 days) later even if no score has 
been recorded between the two days.  Missing symptom score values will be handled as 
described in Section 9.2. The number of days to resolution will be analyzed with a  Cox 
proportional hazards model with covariates (baseline aggregate FLU -PRO Plus© score fo r the 
five COVID -19 symptoms, baseline serum 25D, and body weight).  
As a sensitivity analysis of the resolution of symptoms, a tippi[INVESTIGATOR_209035], with no  missing 
interval, followed by [CONTACT_209063] -day interval, that is, 1, 
2 and 3 missing days between the two consecutive qualifying scores . 
Subgroup analyses for the primary efficacy endpoints will be based on age (≤40 or >40 years), 
severity of the selected five COVID -19 symptoms at baseline ( aggregate FLU -PRO Plus© score 
of ≤ or > the median score ), attained serum 25D at Day 14 (below, withi n or above the targeted 
range of 50 to 100 ng/mL), body weight (≤100 or >100 kg), body mass index ( BMI; ≤30 or >30), 
dosing compliance (<80% or ≥80%), gender, race, ethnicity, comorbidities (<1 or ≥1), duration 
of treatment (≤10 or >10 days) and prior or intercurrent COVID -19 vaccination and/or 
monoclonal antibody therapy for COVID -19.   
In addition, the number of days to resolution of the five aggregated symptoms will be compared 
based on the serum 25D level at Day 14 (<50  ng/mL vs  50 to 100 ng/mL  and 50 to 100 ng/mL 
vs >100 ng/mL ), regardless of the assigned treatment group.  The comparison will be done 
using a Chi -square test.  Frequency of relapses will be calculated, if possible, to account for 
potential worsening of symptoms after resolution (defined immediately above), with relapse 
being defined as achieving a n aggregate FLU -PRO Plus© score > 5 for a min imum of three 
consecutive days.   
The following secondary endpoints will be tested  statistically with methods described below, 
and the nominal p -value will be reported for evaluation :   
1. The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry 
or hacking cough, body aches and pains, and chills and shivering), as measured by [CONTACT_209062] -
PRO Plus© questionnaire , with resolution defined as the first aggregate symptom score of 
≤5 which is maintained for a minimum of three consecuti ve days  (see Section 5.2) , with no 
individual symptom score >1 ;  
2. Resolution , defined as the first score of ≤5 which is maintained for a minimum of three 
consecutive days (without subsequent relapse),  for the aggregate five COVID -19 symptoms 
(trouble breath ing, chest congestion , dry or hacking cough, body aches and pains, and chills 
and shivering)  and for each individual symptom, defined as a score of 0 or 1,  as measured 
by [CONTACT_209062] -PRO Plus© questionnaire  as of Day 10 ; 
3. Incidence of emergency room/urgent care visits;  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
CTAP101  | CTAP101 -CL-2014 | CTAP101 -CL-2014 Protocol 
VV-TMF -183735 | Version 8.0 dated 16 Nov 2021 
 
Protocol CTAP101 -CL-2014 OPKO Pharmaceuticals,  LLC 
CTAP101  (calcifediol) Extended -release  Capsules   Page 12 of 82 
 
4. Incidence of oxygen saturation below 94% (without supplemental oxygen);  
5. Incidence of hospi[INVESTIGATOR_602] (mean duration of hospi[INVESTIGATOR_209036]);  
6. Incidence of requirement for mechanical ventilation; and,  
7. Mortality rate (as incidence). 
 
Endpoints listed will be summarized. For the analysis of individual symptoms in endpoint #2 
above, the threshold of ≤1 is appropriate because it describes minor symptom severity (at worst 
"a little bit") which seems unlikely to presage a poor outcome. Analysis of the resolution of 
individual symptoms will be performed using a logistic regression, with baseline symptom 
score, baseline 25D level, and body weight as covariates. Analysis of the secondary endpoints 
based on incidence will be performed with a Chi-square test. Mean duration will be analyzed 
with analysis of covariance (ANCOVA). Mortality will be analyzed as incidence, with logistic 
regression with baseline symptom score, baseline 25D level and body weight as covariates. 
Rates only will be reported if there are too few deaths to be formally analyzed. 
The severity, duration and clinical course of COVID-19 illness will be compared between treatment groups by [CONTACT_209064]-of-life assessments recorded on the FLU-PRO 
Plus
© questionnaire. Five of the six items from the questionnaire to be analyzed are: “Overall, 
how severe were your infection symptoms today?”, “Overall, how were your infection 
symptoms today compared to yesterday?”, “How much did your infection symptoms interfere 
with your usual activities today?”, “Have you returned to your usual activities today?”, “In 
general, how would you rate your physical health today?”, and “Have you returned to your 
usual health today?” The scores for: symptom severity range from 0 (no infection symptoms 
today) to 4 (very severe); symptoms today range from 1 (much better) to 7 (much worse); 
symptom interference range from 1 (not at all) to 5 (very much). The first of two consecutive 
scores of ≤[ADDRESS_249837] three days and no more than five days will be considered the day 
of resolution, provided that no intervening scores of >1 are recorded. The scores for return to 
usual activities or health are either “yes” or “no”, and the first occurrence of “yes” will be 
deemed to be day of resolution provided that a second “yes” is recorded no more than 5 days 
later without an intervening “no”. The remaining sixth item to be analyzed is: “physical health 
range from 1 (poor) to 5 (excellent). The first of two consecutive scores of >[ADDRESS_249838] three days and no more than five days will be considered the day of resolution, provided that no 
intervening scores of <4 are recorded. Each item will be compared between treatment groups 
using a Cox proportional hazards model with covariates (aggregate FLU-PRO Plus
© score for 
the selected five COVID-19 symptoms at baseline, serum total 25D at baseline, and body weight).  
The clinical course of COVID-19 will be examined by [CONTACT_209065] 25D 
levels <50 ng/mL, 50 to 100 ng/mL and >100 ng/mL at Days 7, 14, [ADDRESS_249839] meet the following criteria to be enrolled and randomized into one of the two 
treatment groups of this study: 
1) Male  or female ≥18 years of age; 
 
__________________________________________________________________________________________________ Confidential  
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 13 of 82 
 
Confidential    
   
 2) Confirmed within the past [ADDRESS_249840] ; 
3) Confirmed to have only mild or moderate COVID -[ADDRESS_249841] of the patient 
reported scores obtained during screening which meets the criterion of  a FLU -PRO  Plus© 
score of ≥ 1.[ADDRESS_249842]/respi[INVESTIGATOR_209037]/systemic domains, and the 
absence of clinical signs indicative of more severe disease  (eg, oxygen saturation < 94% 
on room air or respi[INVESTIGATOR_41351] > 30  bpm); 
4) Represents on self -assessment that the current COVID -19 symptoms are not consistent 
with usual health and that they are the same or worse than on the previous day;  
5) Willing to limit th e use of vitD therapi[INVESTIGATOR_209038] (eg, milk) during the course of the 6-week study;  
6) Must demonstrate the ability to comply with all study requirements; and,  
7) Must be without any disease state or physical cond ition that might impair evaluation of 
safety or which, in the investigator’s opi[INVESTIGATOR_1649], would interfere with study participation.   
Exclusion Criteria:  
Subjects who meet any of the following criteria will be excluded from the study:  
1) Clinical signs indicative of severe or critical COVID -19 disease  (eg, oxygen saturation < 
94% on room air or respi[INVESTIGATOR_1487] > 30  bpm); 
2) Pregnant or lactating women who are breastfeeding;  
3) Use of systemic glucocorticoid medications in the last six months;  
4) Recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, 
hypercalciuria and/or hypercalcemia;  
5) History of a chronic granuloma -forming disease (eg, sarcoidosis);  
6) History of tuberculosis or histoplasmosis;  
7) History of chronic liver disease;  
8) History (previous  12 months) of cardiac event indicative of chronic cardiovascular  
diseases including congestive heart failure, poorly controlled hypertension and 
arrhythmias ;  
9) History in the past five years of multiple m yeloma or carcinoma of the breast, lung or 
prostate;  
10) Any surgical or medical condition which might significantly alter the absorption, 
distribution, metabolism, or excretion of vitD or 25D (eg, small bowel resection , history 
of Crohn’s disease or ulcerativ e colitis ); 
11) Ongoing treatment with thiazide  diuretics;  
12) History of hyperphosphatemia, hyperuricemia and gout;  
13) Renal impairment measured as eGFR< 15 mL/min/1.73m² on serum creatinine in the last 
three months ; 
14) Serum calcium ≥9.8 mg/dL in the last three months ; 
15) Evidence of existing or impending dehydration;  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 14 of 82 
 
Confidential    
   
 16) Known or suspected to have hypersensitivity to any of the constituents of the study drug; 
and/or,  
17) Currently participating in, or have participated in, an interventional/investigational study 
within [ADDRESS_249843], DOSE, AND ROUTE OF ADMINISTRATION   
Rayaldee (CTAP101 Capsules)  in a 900 mcg loading dose split into three equal doses of 300 
mcg each administered over three days ( on Day s 1, 2 and 3 ) followed by a maintenance dose of 
60 mcg per day for the subsequent 24 days (Days 4-27). Doses will be administered orally  at 
bedtime after fasting for at least [ADDRESS_249844], DOSE AND ROUTE OF ADMINISTRATION   
Placebo in a look -alike 900 mcg loading dose split into three equal doses of 300 mcg each 
administered over three days ( on Day s 1, 2, and 3 ) followed by a look -alike maintenance dose 
of 60 mcg per day for the subsequent 24 days (Days 4-27).  Doses will be administered orally at 
bedtime after fasting for at least [ADDRESS_249845] 3 hours after administration of study drug . 
Duration of study  
Forty-five days 
Concomitant Medications  
Allowed, with the exception of:  
1) Calcitriol, paricalcitol and doxercalciferol;  
2) Thiazide  diuretics ;  
3) Medication s that could impair the absorption of fat -soluble nutrients; and,  
4) Dietary supplements providing in excess of 0.55 g of elemental calcium per day.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249846]  aspartate aminotransferase  
AUC  area under the (concentration) curve  
BA bioavailability  
b-hCG  beta-human chorionic gonadotropin  
BMI  body mass index  
bpm breaths per minute  
CAMP  cathelicidin antimicrobial peptide  
CFR  Code of Federal Regulations  
CKD  chronic kidney disease  
Cmax maximum concentration  
COVID -[ADDRESS_249847] 
ECG  Electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
eGFR  estimated glomerular filtration rate  
ER 
ET extended -release  
early termination  
FAS full analysis set  (or population)  
FDA  Food and Drug Administration  
FU follow -up 
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
HDPE  high-density polyethylene  
HIV(1)  human immunodeficiency virus (type 1)  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249848] parathyroid hormone  
IRB/EC  Institutional Review Board/Ethics Committee  
IRT interactive response technology  
ISF investigator site file  
ITT Intent -to-Treat  
LAR  legally authorized representative  
MedDRA  Medical Dictionary for Regulatory Activities  
PAMP s pathogen -associated molecular patterns  
PBMCs  peripheral blood mononuclear cells  
PE physical examinations  
PK pharmacokinetic(s)  
PP per-protocol  
PTH  parathyroid hormone  
RT-PCR  reverse transcription polymerase  chain reaction  
SAE  serious adverse event  
SARS -CoV -[ADDRESS_249849]  vitamin D receptor  
VDRE  vitamin D response element  
VitD  vitamin D  
VS vital signs  
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 17 of 82 
 
Confidential    
   
 1 INTRODUCTION  
1.1 Vitamin D Insufficiency  
Calcifediol is 25 -hydroxyvitamin D 3 (25D 3), the physiological precursor to the  active  vitamin D 
(vitD) hormone, 1,25 -dihydroxyvitamin D 3 (calcitriol  or 1,25D 3). This prohormone is 
synthesized by [CONTACT_149246] D 3 (cholecalciferol) generated endogenously in ski n 
following exposure to sunlight or obtained from the diet or supplements. Another prohormone, 
25-hydroxyvitamin D 2, is synthesized hepatically from vitamin D 2 (ergocalciferol), which cannot 
be produced endogenously but is obtained only from the diet or su pplements. These two 
prohormones are collectively referred to as “25 -hydroxyvitamin D (25D)” . Unless an individual 
is receiving significant ergocalciferol supplementation, essentially all of the 25D in blood 
consists of calcifediol.  
It is widely accepted that serum total 25D is the best indicator of a patient’s vitD status. Serum 
total 25D levels of ≥30 ng/mL are currently conside red adequate  while levels of <30 ng/mL are 
considered “insufficient” [ Holick et al 2011 ]. The com monly used reference range for serum 
total 25D is 30 to 100 ng/mL [ Souberbielle et al 2010 ]. Levels of serum total 25D in the general 
population vary according to many factors, including intensity of sunlight (varying w ith 
geographic location and season), exposure to sunlight (affected by [CONTACT_209066][INVESTIGATOR_371], use of 
sunscreen and other cultural factors), age and dietary intake [ Holick 1995 ]. Levels tend to be 
lower during the winter and at hi gher latitudes. VitD deficiency (<20 ng/mL) in the US is most 
common in pi[INVESTIGATOR_49194] (decreased vitD production in skin) and obese (increased volume of 
distribution of vitD due to adiposity ) subjects, the same population that appears to be most 
susceptible to  infection with SARS -CoV -2. 
Serum 25D levels above of 40-60 ng/mL have recently been recommended to reduce the risk of 
infection with severe acute respi[INVESTIGATOR_7686] 2 ( SARS -CoV -2) and higher levels are thought 
to be useful for patients who become infect ed [Grant et al, 2020 ]. Serum levels of  ≥50 ng/mL 
have recently been shown to be required for 25D to modulate vitD-responsive endpoints in 
patients with chronic kidney disease (CKD), probably via activation by [CONTACT_209067],  
extra -renal CYP27B1 [ Strugnell et al, 2019 ]. It appears likely that similar high levels are 
required for 25D to be activated in vivo  by [CONTACT_097]27B1 expressed in virus -stimulated 
macrophages.  
1.[ADDRESS_249850] v iral pathogens. 
High levels of v itD has been associated with  resistance to human immunodeficiency virus type 1 
(HIV1 ) infection  [Jimenez -Souza et al  2018 ]. Moreover, low levels of v itD have been associated 
with higher levels of immune activation and inflammation in HIV and other diseases [ Jimenez -
Souza  et al 2018 ]. While the resul ts of clinical trials studying v itD supplementation to r educe 
acute respi[INVESTIGATOR_209039], there are several well designed large met a-
analyses that have supported v itD supplemen tation as being safe and protective against acute 
respi[INVESTIGATOR_209040] [ Martineau et al  2017 ; Bergman et  al 2013]. CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249851]’s immune response to the virus. Arguably the 
most effective , endogenous antimicrobial agent known to man, LL37 is the product of the 
endogenous human cathelicidin antimicrobial peptide (CAMP ) gene and is secreted from 
monocyte/ macro phages , dendritic cells and neutrophils in response to viral or bacterial infection 
[Nizet et al 2001 ].  Expression and secretion of LL37, along with numerous other endogenous 
antimicrobial activities, requires induction and p riming. A key regulatory signal that can prime 
human macrophages for rapid and robust antimicrobial responses, including deployment of LL37 
at the site of infection, is vitD, specifically calcifediol or 25D [ Gombart et al 2009 ]. Like a 
loaded weapon with the safety left on, macrophages without sufficient serum total 25D as 
substrate are rendered unable to release LL37, and thus protect the host.  
The innate immune response in antigen -presenting cells (monocyte/macrophages a nd dendritic 
cells) is initiated and perpetuated by [CONTACT_209058] -associated molecular patterns (PAMP s) derived 
from the cell wall and other unique signatures of the infecting virus interacting with pattern 
recognition receptors (eg, Toll -like receptors [TLR]).  TLR activation eventually leads to up -
regulation of expression of the intracellular vitD receptor (VDR) and CYP27B1 (25D -1α-
hydroxylase); the latter event up -regulates generation the active vitD metabolite, 1,25 -
dihydroxyvitamin D (1,25D). That 1,25D can then engage the  VDR in an intracrine mode  and 
controls CAMP  and interleukin 1ß (IL -1ß) gene expression; IL -1ß is a central initiator of the 
adaptive immune response.  
Using upregulated expression of the potent endogenous antimicrobial CAMP  mRNA by [CONTACT_209068] /macrophages as an ex vivo  read-out, extensive recent work [ Rosen 
et al 2012 ; Liu et al 2006 ; Adams et al 2007 ; Krutzik et al 2008 ; Liu et al 2009 ; Edfeldt et al  
2010 ; Fabri et al 2011 ; Montoya et al 2014 ; Chun et al 2014 ; Srikanth et al 2016 ] shows that 
insufficient serum levels of 25D (VDI) in the host induces an immune -compromised state. An 
insufficient level of 25D in hu man serum causes inadequate i) intracellular generation of 1,25D, 
ii) activation of the VDR, iii) transactivation of the CAMP  gene and iv) production and release of 
LL37 to combat microbial invasion of the host. The end result is innate and subsequent adap tive 
immune deficiency.  
Raising serum total 25D to sufficiently high levels can resolve the immune -compromised state in 
the human host. Accomplishing this with vitD supplements is unreliable  and is difficult in 
obesity owing to the increased volume of dis tribution of the non -polar vitamin. In contrast, 
treatment with the more polar and extended -release calcifediol  (Rayaldee or CTAP101 Capsules)  
is reliable and, depending on the administered dose, can take as little as 9-12 hours. Treatment 
with CTAP101 Cap sules  has been shown to be safe for administration to patients with sta ge 3 or 
4 CKD , as evidenced by [CONTACT_209060] (US) Food and Drug Administration (FDA) approval of 
the product in 2016 as Rayaldee® (calcifediol) Extended -release Capsules.   
Accumulating  data suggest that hyperactive immune response to COVID -[ADDRESS_249852] the depletion and exhau stion of T 
cell populations [ Diao et al 2020 ]. On the other hand, vitD is an immune -modulating agent and 
has been implicated in the pathophysiology of autoimmune diseases, including systemic lupus CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 19 of 82 
 
Confidential    
   
 erythematosus  and multiple scl erosis. VDI is a risk factor for multiple sclerosis and correlates 
with the disease severity. Thus,  
 appropriate treatment with Rayaldee may help to mitigate 
an overactive , adaptive  T- and B -lymphocyte immune system response to the virus and 
ameliorate immune cell exhaustion  [Adams et al 2007 ; Rosen et al 2012 ]. 
1.4 Preclinical Experience  
Toxicity associated with calcifediol is consistent with that observed due to vitD overdose and is 
similar to that seen with 1,25D or calcitriol . Generally, such toxicity is subsequent to 
hypercalcemia. To study the toxicity of CTAP101 Capsules , an earl ier formulation of CTAP101  
Capsules  was administered to dogs for 3 months and resulted in typi[INVESTIGATOR_209041]-induced 
hypercalcemia, hypercalciuria, soft tissue mineralization (eg, kidney, stomach, aorta and heart) 
and death.  Severe adverse reactions to CTAP101 Capsules  were observ ed in dogs treated with 
500 or 1 ,000 mcg per day  and were associated with serum 25D or calcifediol levels >450  ng/mL 
following 1 month of treatment.  
Using the current formulation of CTAP101 Capsules , dogs were treated daily for three  months 
with doses up t o 45 mcg (~4.5 mcg/kg/day).  No signs of toxicity were observed at the highest 
dose tested which was associated with serum calcifediol levels >150 ng/mL.   
Calcifediol administration (orally through addition to the diet) to rats for 6 months  has been 
report ed to produce signs of toxicity at daily doses >40 mcg/kg. Toxicities included an increased 
incidence of nephrocalcinosis and uroliths.   
Results from in vitro  drug release and nonclinical pharmacokinetic ( PK) studies in male Yucatan 
swine (CTAP101 -PK-0012 ) demonstrate that CTAP101 Capsules  have an extended -release ( ER) 
profile. In swine, the bioavailability (BA) of calcifediol following the administration of 
CTAP101 Capsules  was approximately 30% lower than that from an immediate -release capsule 
preparation. Further, a delay in the release of the active ingredient (time of maximum 
concentration or tmax >7 hours) was observed as compared to the immediate -release formulation 
(tmax ~4 hours).  
1.5 Previous Clinical Experience  
Rayaldee (CTAP101 Cap sules)  (30 mcg/capsule) have been approved by [CONTACT_209069] ( SHPT ) in adults with stage 3 or 4 CKD and VDI, 
defined as serum total 25D levels less than 30 ng/mL. The clinical studies which supported FDA 
appro val are described below.  
There have been three  previous single -dose phase 1 studies with CTP101 Capsules  (CTAP101 -
CL-1005, CTAP101 -CL-1011  and CTAP101 -CL-1016 ), two phase 2 studies, of which one was a 
single -dose study ( CTAP101 -CL-2004 ) and one was a repeat -dose study ( CTAP101 -CL-2008 ), 
and three phase 3 studies ( CTAP101 -CL-3001, CTAP101 -CL-3002  and CTAP101 -CL-3003 ).  
Studies CTAP101 -CL-1011 , CTAP 101-CL-1016  and CTAP101 -CL-2008 were conducted with 
the current  formulation of CTAP101 Capsules  (30, 60 or 90 mcg per capsule) . Two of the phase 
3 studies ( CTAP101 -CL-3001  and CTAP101 -CL-3002 ) were  identical double -blind, placebo -
controlled pi[INVESTIGATOR_149212]  (CTAP101 -CL-3003) was a follow -on open-label extension CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 20 of 82 
 
Confidential    
   
 trial.  All phase 3 trials were conducted with the current formulation of CTAP101 Capsules (30 
mcg per capsule).  
The single -dose studies confirmed the  ER characteristics of the investigational drug product and 
that the current formulation has a BA of approximately 25%  when administered i n the fasting 
state. Administration of a single  supraphysi ologic dose of CTAP101 Capsules  following a high-
fat, high calorie meal resulted in a significantly higher exposure of calcifediol compared to when 
administered in a fasted state. An approximate 5 -fold increase in the maximum concentration 
(Cmax) in the blood and a 3.5 -fold increase in area under the concentration curve ( AUC ) was 
observed in the fed group compared to the fasted group  (CTAP101 -CL-1016 ). 
In CTAP101 -CL-2008 , a double -blind, placebo -controlled, randomized repeat -dose phase 2 
study, daily administration of CTAP101 Capsules  increased serum total 25D levels to ≥30 ng/mL 
in nearly  all subjects and decreased mean plasma intact parathyroid hormone ( iPTH ) from 
baselin e and compared to placebo during 6 weeks o f treatment  [Sprague et al, 2014 ]. The mean 
% decrease in plasma iPTH from baseline in the per-protocol ( PP) population was related to the 
administered dos e: -20.9, -32.8, and -39.3 for the 30, 60 and 90 mcg groups, respectively .   
The efficacy was confirmed in a larger  phase 3 program with nearly all subjects (97%)  treated 
with CTAP101  Capsules  who completed the program  without a major protocol deviation 
achieving a norma l serum total 25 D level and with 50% of such subjects achieving a mean 
reduction in  plasma  iPTH from baseline of at least 30%.  Fewer than 9% of placebo subjects 
achieved a 30% reduction in plasma iPTH or achi eved a normal 25 D level.  
CTAP1 01 Capsules  did not cause significant adverse effects on serum  calcium or phosphorus.  
Treatment -emergent adverse events (TEAEs), including those related to the investigational study 
drug, were comparable across treatment groups, except for hyperphosphatem ia which was 
observed in four subjects, none of which was considered by [CONTACT_209070] s tudy drug.   Subjects in phase 3 trials who were treated with CTAP101 Capsules 
experience a mean increase in serum calcium of 0.2 mg/dL during a 26 -week treatment period 
compared with a mean increase of 0.1 mg/dL in subjects treated with placebo.  Most (74%) of 
the subjects treated with CTAP101 Capsules received a dose of 60 mcg/day.  A total of 4.2% of 
the active -treated subjects and  2.1% of placebo -treated subjects experienced at least 1 elevation 
in serum calcium above the upper limit of normal (10.5 mg/dL), none of which were clinically 
significant.  
For all clinical studies, the adverse event (AE) profiles did not identify any eve nts specific to 
CTAP101 Capsules . After both single and repeat -dose administration, CTAP101 Capsules  were 
generally well -tolerated.  The overall treatment -emergent AE profile in the phase 3 program was 
comparable between CTAP101 Capsules  and placebo groups.  Subjects receiving CTAP101 
Capsules  had a greater increase in  mean  serum corrected calcium (P<0.001) than placebo 
patients (0.2 versus 0.1 mg/dL ); for serum phosphorus, subjects receiving CTAP101 Capsules  
had a greater mean increase  than placebo patients (0.2 versus 0.1 mg/dL ). 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 21 of 82 
 
Confidential    
   
 2 STUDY OBJECTIVES  
2.1 Study Objectives  
2.1.1 Primary Objectives  
The primary objectives of this study are to compare  the effects of Rayaldee (CTAP101 Capsules)  
vs. placebo treatment in patients with mild to moderate COVID -19 on the:  
1) Attainment of serum total 25D levels at or above 50 ng/mL by [CONTACT_2006] 14; and,    
2) Severity  and duration  of disease  as evidenced by [CONTACT_209061] -19 symptoms (trouble 
breathing, chest congestion, dry or hacking co ugh, body aches and pains, and chills and 
shivering) using the FLU -PRO Plus© questionnaire as the data collection tool.  
2.1.[ADDRESS_249853] unresolved  
symptoms of mild to moderate COVID -19 in (a) the attainment of serum total 25D levels ≥50 
ng/mL as assessed at Day 14, and (b) the number of days to resolution of five  symptoms (trouble 
breathing, chest congesti on, dry or hacking cough, body aches and pains, and chills and 
shivering), as measured by [CONTACT_209062] -PRO Plus© questionnaire  with resolution defined as the first 
aggregate FLU -PRO Plus© symptom score of ≤5 which is maintained for a minimum of three 
consecutiv e days.  
2.1.3 Secondary Objectives:  
The secondary objectives are to compare  the effects of Rayaldee (CTAP101 Capsules) vs. 
placebo treatment on:  
1) The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry 
or hacking cough, body aches and pains, and chills and shivering), as measured by [CONTACT_209062] -
PRO Plus© questionnaire , with resolution defined as the first aggregate symptom score of ≤5 
which is maintained for a minimum of three consecutive days, with no individual symptom 
score >1 ;  
2) Resolution, defined as the first score of ≤5 which is maintained for a minimum of three 
consecutive days (without subsequent relapse) , for the aggregate five COVID -19 symptoms 
(trouble breathing, chest congestion, dry or hacking cough, body aches and pai ns, and chills 
and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by 
[CONTACT_209062] -PRO Plus© questionnaire as of  Day 10;  
3) Incidence of emergency room /urgent care  visits;  
4) Incidence of oxygen saturation below 94%  (without oxyg en supplementation) ; 
5) Incidence and duration of hospi[INVESTIGATOR_602];  
6) Incidence of r equirement for mechanical ventilation;  
7) Mortality rate  (as incidence) ; 
8) Severity and duration of COVID -19 illness as evidenced by [CONTACT_102767] -of-life measures  using 
the FLU -PRO  Plus© questionnaire ; and,  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 22 of 82 
 
Confidential    
   
 9) Clinical course of COVID -19 as a function of ser um 25D concentrations of <50 ng/mL, 50 
to 100 ng/mL and >10 0 ng/mL at Days 7, 14,  21 and 28 , defined as the proportion of 
subjects in each treatment group with a total score of ≤5 for fi ve symptoms (trouble 
breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and 
shivering) using the FLU -PRO Plus© questionnaire .  
  
 
 
  
  
  
  
  
  
  
   
  
  
 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 23 of 82 
 
Confidential    
   
 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design  
This is a phase 2, single or multi -center, randomized, double -blind placebo -controlled study to 
evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules)  to treat adult subjects with 
unresolved symptoms of mild to moderate COVID -[ADDRESS_249854] positive for SARS -CoV -2 via 
nasopharynx swa b and subsequent reverse transcription polymerase chain reaction (RT -PCR)  or 
any substitutable FDA -authorized diagnostic test . Subjects will be randomized to receive either 
oral Rayaldee (CTAP101 Capsules)  or matching placebo administered according to the 
following regimen: a loading dose (900 mcg  split into three equal doses of 300 mcg each 
administered on Day s 1, 2 and 3 ) followed by 24 daily maintenan ce doses (60 mcg on Days 4 to 
27) administered at bedtime  after fasting for at least 3 hours  following  dinner .  
3.2 Rationale for Study Design and Control Group  
The proposed study design is based on the  hypothesis  that the severity  and duration of COVID -
19 symptoms will be attenuated with an increase  of serum 25D to levels of  ≥50 ng/mL.  A 
placebo -controlled trial is appropriate because there is currently no therapy that has been 
demonstrated to be effective in treating COVID -19 symptoms . 
The FLU -PRO  Plus© questionnaire [Powers et al, 2016  and 2018 ] will be used by [CONTACT_209071] -assess their COVID -19 symptoms on a daily basis  at bedtime .  This questionnaire 
was specifically designed and validated to evaluate in clinical trials the presence, severity and 
duration of symptoms associated  with viral infections.  It contains 32 items, grouped into 6 
domains, that provide a comprehensive evaluation of such symptoms.  It supports the primary 
efficacy endpoint of t he time to resolution of five COVID -19 symptoms (trouble breathing, chest 
congest ion, dry or hacking cough, body aches and pains, and chills and shivering), defined as a 
reduction in the aggregate FLU -PRO Plus© symptom score for these five symptoms recorded at 
study drug initiation (Day 1) to or below [ADDRESS_249855]/respi[INVESTIGATOR_209037]/systemic domains of the FLU -PRO Plus© 
questionnaire for which average scores of ≥1.[ADDRESS_249856] congestion and dry or hacking c ough are symptoms indicative of potentially 
inadequate oxygenation and an impending requirement for supplemental oxygen and 
hospi[INVESTIGATOR_059]. Body aches and pains and chills and shivering are symptoms indicative of 
systemic inflammatory responses associated  with active viral infection.  Resolution of each of 
these five symptoms will be analyzed separately, as well, as secondary efficacy endpoints.  
COVID -19 patients are expected to (but may not) present with serum total 25D levels averaging 
approximately 20 -25 ng/mL, unless vit D becomes acknowledged as a possible prophylaxis 
against SARS -CoV -2 infection, based on information gathered from OPKO’s prior PK studies 
conducted in healthy  US volunteers and based on information from many US studies published 
in the m edical literature. CKD is known risk factor for COVID -19 and p atients with CKD will 
present with even lower 25D levels as advancing kidney disease is known to be associated with 
declining 25D levels [ Levin et al 2007 ]. Phase [ADDRESS_249857] shown that baseline serum total 25D levels average below 20 
ng/mL [ Sprague et al 2016 ]. Further, these studies have shown that Rayaldee is safe in the CKD 
population at the proposed doses.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249858] stage 3 or 4 CKD, defined as an estimated 
glomerular filtration rate (eGFR) of 15 to <60 mL/min/1.73m2. 
Data from Studies CTAP101 -CL-1011,  CTAP101 -CL-1020  and 170074 show that a n oral 
loading dose of 900 mcg of Rayaldee (CTAP101 Capsules)  in the fasting state (approximately 
25% BA) will raise serum 25D levels within ~ 9-12 hours by [CONTACT_2902] 20 -35 ng/mL, depending on 
the subject’s body weight (the higher the body weight, the lower the expected increase in 25D). 
Many COVID -[ADDRESS_249859] higher than normal body mass index (BMI) 
values in view of the latest reported US data. Each maintenance dose of Rayaldee (CTAP101 
Capsules)  (60 mcg/day) will incr ease serum 25 D by [CONTACT_20904] 0.6 ng/mL, as shown in Studies 
CTAP101 -CL-3001, CTAP101 -CL-3002  and CTAP101 -CL-3003  [Sprague et al, 2016 ]. It 
follows that subjects having a baseline 25D level of ~25 ng/mL will reach ~45 -60 ng/mL after 
the loading dose and ~ 59-74 ng/mL after [ADDRESS_249860] s who ha ve a higher baseline 25D level.  For this reason, 25D levels will be checked 
at Day s 7, 14 and 21 and dosing will be adjusted  if levels exceed 100 ng/mL.  FDA has approved 
Rayaldee (CTAP101 Capsules)  to raise levels up to a target of 100 ng/mL in kidney patients (see 
APPENDIX  2.: Package Insert).  
3.3 Evaluations  
Blood samples  will be acquired periodically during the study (see APPENDIX  1: Schedule of 
Events) . Blood samples will be assayed for: i) serum total 25D (primary efficacy measure) ,  
iv) plasma iPTH, v) clinical ch emistries 
and hematology, and markers of the 
adaptive immune response to SARS -CoV -[ADDRESS_249861] using the FLU -PRO  Plus© 
questionnaire.   
3.4 Study Endpoin ts  
3.4.1 Primary Efficacy Endpoints  
The primary efficacy endpoint s are:   
1) Attainment of serum total 25D levels at or above 50 ng/mL, as assessed at Day 14; and,  
2) The number of days to resolution of the selected five COVID -19 symptoms  (trouble 
breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and 
shivering) , defined as a reduction in the aggregate symptom score recorded on Day 0 (prior CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 25 of 82 
 
Confidential    
   
 to study drug initiation) by [CONTACT_209062] -PRO Plus© questionnaire to or below 5 for a minimum 
of three consecutive days. A statistically significant difference (P<0.025 one sided ) between 
the treatment groups in the time to resolution of symptoms in favor of treatment with 
CTAP101 Capsules will be deemed a successful outcome.     
On each day during the  study , subjects  will record once daily ( during a [ADDRESS_249862] goes to sleep) the severity of COVID -19 symptoms using  the 
FLU -PRO  Plus© questionnaire.   
3.4.2 Secondary  Efficacy Endpoints  
The secondary endpoints are  : 
1. The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry 
or hacking cough, body aches and pains, and chills and shivering), as measured by [CONTACT_209062] -
PRO Plus© questionnaire , with resolution defined as the first aggregate symptom score of ≤5 
which is maintained for a minimum of three consecutive days , with no individual symptom 
score >1;  
2. Resolution , defined as the first score of ≤5 which is maintained for a minimum of three 
consecutive days  (without subsequent relapse) , for the aggregate five COVID -19 symptoms 
(trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills 
and shivering) and for each individual symptom, defined as a score of 0 or 1 , as measured by 
[CONTACT_209062] -PRO Plus© questionnaire a s of Day 10;  
3. Incidence of emergency room /urgent care  visits; 
4. Incidence of oxygen saturation below 94%  (without supplemental oxygen) ; 
5. Incidence and duration of hospi[INVESTIGATOR_602];  
6. Incidence of the r equirement for mechanical ventilation;  
7. Mortality rate  (as incidence) ;  
8. Severity and duration of COVID -19 illness as evidenced by [CONTACT_102767] -of-life measures 
including ability to perform usual activities and opi[INVESTIGATOR_209042], using  the 
FLU -PRO  Plus© questionnaire;  and, 
9. Clinical course of COVID -19 as a function of ser um 25D concentrations of <50 ng/mL, 50 to 
100 ng/mL and >10 0 ng/mL at Days 7, 14,  21 and 28 , defined as the proportion of subjects in 
each treatment group with a total score of ≤5 for the selected five COVID -19 symptoms 
(trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills 
and shivering) using the FLU -PRO Plus© questionnaire .   
Endpoint items 3-7 are all based on incidence over the entire 42 day study period.  
Once daily (during a 24 hour period starting in the evening before bedtime), subjects will record 
their ability to perform usual activities and their opi[INVESTIGATOR_209043] a diary using 
FLU -PRO© Plus questionnaire.  
3.4.3 Explorat ory Endpoints  
The exploratory endpoints include:  
 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 26 of 82 
 
Confidential    
   
  
 
 
 
 
 
  
  
 
 
  Baseline is defined as values obtained 
at Visit 1.  
3.4.4 Primary Safety Endpoints  
The safety and toler ability of Rayaldee (CTAP101 Capsules)  will be evaluated by [CONTACT_2695], physical 
examinations (PE ), vital signs (VS), electrocardiograms (ECGs), hematology and clinical 
chemistries. Special attention will be given to changes in the following parameters:  
1) Serum total calcium (corrected for  serum albumin);  
2) Serum phosphorus;  and, 
3) eGFR.  
3.[ADDRESS_249863] enrollment (first subject consented) to study completion for the  last subject (last subject 
out/last visit complete ). Each enrolled subject will participate in the study after randomization for 
up to 42 days (Day 1 through D ay 42). 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249864] meet the following criteria to be enrolled and randomized into one of the two 
treatment groups of this study:  
1) Male or female  ≥ 18 years  of age ;  
2) Confirmed within the past [ADDRESS_249865]; 
3) Confirmed to have only mild or moderate COVID -[ADDRESS_249866] of the patient 
reported scores obtained during screening which meets the criterion of a FLU -PRO  Plus© 
score ≥  1.[ADDRESS_249867]/respi[INVESTIGATOR_209037]/systemic domains, and the absence of 
clinical signs indicative of more severe disease  (eg, oxygen saturation < 94% on room air or 
respi[INVESTIGATOR_2844] >30  bpm); 
4) Represents on self -assessment that the current COVID -19 symptoms are not consistent with 
usual health and that they are the same or worse than on the previous day;  
5) Willing to limit the u se of vitD therapi[INVESTIGATOR_209044] (eg, milk) during the c ourse of the 6-week study ; 
6) Must demonstrate the ability to comply with all study requirements ; and, 
7) Must be without any disease state or physical condition that might impair evaluation of 
safety or which, in the investigator’s opi[INVESTIGATOR_1649], would interfere with study participation.   
4.3 Exclusion Criteria  
Subjects who meet any of the following criteria will be ex cluded from the study : 
1) Clinical signs indicative of severe or critical COVID -19 severity  (eg, oxygen saturation < 
94% on room air or respi[INVESTIGATOR_1487] > 30  bpm); 
2) Pregnant or lactating women who are breastfeeding;  
3) Use of  systemic glucocorticoid medications i n the last six months ; 
4) Recent history (previous 12 months) of primary hyperparathyroidism, kidney stones, 
hypercalciuria and/or hypercalcemia ; 
5) History of a chronic granuloma -forming disease (eg, sarcoidosis) ; 
6) History of tuberculosis or histoplasmosis;  
7) History of chronic liver disease;  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 28 of 82 
 
Confidential    
   
 8) History of (previous 12 months) of cardiac event indicative of chronic cardiovascular  
diseases including congestive heart failure, poorly controlled hypertension and arrhythmias ;  
9) History in the past five years of multiple myeloma or carcinoma of the breast, lung or 
prostate;  
10) Any surgical or medical condition which might significantly alter the absorption, 
distribution, metabolism, or excretion of vitD or 25D (eg, small bowel resection , history of 
Crohn’s disease or ulcerati ve colitis ); 
11) Ongoing treatment with thiazide diuretics ; 
12) History of hyperphosphatemia, hyperuricemia and gout;  
13) Renal impairment measured as eGFR< 15 mL/min/1.73m²  on serum creatinine in the last 
three months ; 
14) Serum calcium ≥9.8 mg/dL in the last three month s; 
15) Evidence of existing or impending dehydration ; 
16) Known or suspected to have hypersensitivity to any of the constituents of the study drug ; 
and/or,  
17) Currently participating in, or have participated in, an interventional/investigational study 
within 30 days prior to study screening . 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 29 of 82 
 
Confidential    
   
 5 STUDY TREATMENTS  
5.1 Description of Rayaldee (CTAP101 Capsules)  
Dosage form:  Soft gel capsule   
Dose strength:  [ADDRESS_249868] description:  Blue oval capsules  printed single -sided, centered with the logo O 
in white.  Each bottle contain s 30 capsules . 
Active component:  Calcifediol  
Non-active components:  Paraffin wax, mineral oil, mono - and diglycerides, dehydrated 
alcohol, lauroyl polyoxylglycerides, butylated hydroxytoluene, 
hypromellose , modified starch, carageenan, sodium phosphate 
dibasic, sorbitol and sorbitan solution, FD&C Blue #1, titanium 
dioxide, medium chain triglycerides (coconut oil)  and ink (white , 
which may contain titanium dioxide , isopropyl alcohol, propylene 
glycol, hydroxypropylmethyl cell ulose 2910 )  
Storage conditions:  20-25°C ( 68-77°F); excursions allowed to 15°C to 30°C (59°F to 
86°F); protect from light and heat . 
5.2 Description of Placebo Capsules  
Dosage form:  Soft gel capsule   
Dose strength:  [ADDRESS_249869] description:  Blue oval capsules  printed single -sided, centered with the logo O 
in white.  Each bottle contains 30 capsules.  
Active component:  None  
Non-active components:  Paraffin wax, mineral oil, mono - and diglycerides, dehydrated 
alcohol, lauroyl polyoxy lglycerides, butylated hydroxytoluene, 
hypromellose, modified starch, carageenan, sodium phosphate 
dibasic, sorbitol and sorbitan solution, FD&C Blue #1, titanium 
dioxide, medium chain triglycerides (coconut oil) and ink (white, 
which may contain titanium dioxide, isopropyl alcohol, propylene 
glycol, hydroxypropylmethyl cellulose 2910)  
Storage conditions:  20-25°C (68 -77°F); excursions al lowed to 15°C to 30°C (59°F to 
86°F); protect from light and heat  
5.3 Treatments Administered  
5.3.1 Dosing Instructions  
Study drug should NOT  be administered to individuals known to be allergic to any component 
of the drug.   CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 30 of 82 
 
Confidential    
   
 Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day 
on Day s 1, [ADDRESS_249870] 3 
hours after administratio n of study drug .  
Study drug will be provided  in containers labeled as investigational study drug as per the 
Packaging and Labeling below in Section 5.9. The interactive response technology ( IRT) will 
dispense an appropriate bottle configuration  to each patient per the dosing requirements . Each 
bottle will contain either active drug or a matc hing placebo.  
Drug accountabili ty will be performed at each v isit until the end of the 28-day treatment  period .  
All procedures being performed during the course of this clinical study are listed sequentially by 
[CONTACT_209072] 7: Study Activities, and may be found as a table in APPENDIX  1: Schedule of 
Events . 
5.3.2 Dose Reduction and Stoppi[INVESTIGATOR_209045] 
(CTAP101 Capsules), any subject who exhibits a confirmed serum total calcium >10.5 and ≤11.0 
mg/dL (corrected for serum albumin) based on blood samples obtained on Days 7 and 14 will 
reduce the daily maintenance dose by [CONTACT_89953] (from 60 mcg to 30 mcg) starting at Day 21.  
The dose will similarly be  reduced based on blood samples obtained on Days 7 and 14 if serum 
total 25D is confirmed to exceed 100 ng/mL, the maximum targeted level in the FDA -approved 
Package Insert for Rayaldee (see APPENDIX  2.), starting at Day 21.  
Subjects who exhibit confirmed serum total calcium >11.0 mg/dL (corrected for serum albumin) 
based on blood samples obtained on Days 7, 14 and 21 will suspend dosing until normalization 
of serum calcium at which time (if applicable) dosing will be resumed at one capsul e per day (30 
mcg per day).  Subjects will be requested to return to the clinic on the earliest possible day of 
their next scheduled visit (eg, Day 12 for the Day 14 visit) for the confirmatory blood draw.  
Subjects who develop severe (CTCAE ≥ 3) abnormalit ies (low or high) of serum phosphorus, 
uric acid or plasma iPTH will be withdrawn from study drug treatment  but will continue in the 
study . 
Enrollment of subjects into the study will be paused if mortality in the treatment arm is ≥ 7% 
higher compared to th e placebo arm until the Data Safety Monitoring Board (DSMB) makes an 
assessment about causality, and may resume once the DSMB deems it acceptable to continue (if 
applicable).  
5.3.[ADDRESS_249871] of general  supportive measures  (eg, phosphate binders for hyperphosphatemia) .  If the 
overdosage  is discovered within a short time, emesis can be induced or gastric lavage performed 
to prevent further absorption. Serial serum calcium  measurements should be obtained and any CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249872] medical care is required if persistent and 
markedly elevated serum calcium levels occur.  Any occurrence of accidental overdose or 
toxicity that requires medical intervention should be reported as an adverse event.  
5.3.4 Method of Assigning Subjects to Treatment Groups   
After signing the informed consent form ( ICF), prior to any study -related activities, each subject  
will be assigned a 5 digit identification number and will retain th is number throughout the study.  
The 5 digit identification number (SS-EEE) will consist of a 2 -digit study  site number (SS) and a 
3-digit consecutive enrollment number ( EEE). Should a subject be withdrawn from the study, 
that subject ’s 5 digit identification number will not be reassigned.   
Approximately 250 subjects will be screened to enroll approximately 160 subjects who meet 
screening criteria. The IRT will provide study treatment group assignments for these subjects 
using a computer -generated randomization code. Subjects will be randomized in a blinded 
manner into 1 of 2 treatment groups (approximately 80 subjects per group) in a 1:1 ratio of 
Rayaldee (CTAP101 Capsules)  or placebo, respectively.  
5.[ADDRESS_249873] s should be willing to limit the use of vitD therapy  and vitD supplements except for 
normally fortified food products (eg, milk) during the course of the 6-week study other than the 
study drug . Standard of care medications  for CKD ( VitD, calcitriol, paricalcitol and 
doxercalciferol) should be suspended during the treatment perio d. Excluded therapi[INVESTIGATOR_209046],  1α-hydroxylated  vitD analogs ( calcitriol , paric alcitol  and 
doxercalci ferol) and vitD supplements (cholecalciferol and ergocalciferol) . Current treatment 
with c ytochrome P450 inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir,  
itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole, which 
may inhibit enzymes involved in vitD metabolism and may alter serum levels of calcifediol , 
must be eva luated by [CONTACT_209073] a reason for exclusion from the study . 
Medications that could impair the absorption of fat -soluble nutrients and d ietary calcium 
supplements providing more than 0.[ADDRESS_249874] Activity Restrictions  
Subjects should maintain their usual pattern of sun exposures and activities  as allowed under any 
health, government or local isolation/quarantine or  personal -protection requirements for infection 
containment.  
5.[ADDRESS_249875] the possibility to become pregnant (not surgically sterile or 
postmenopausal) and male subjects with female partners who have the possibil ity to become 
pregnant must agree to use effective contraception (such as implants, injectables, combined oral CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 32 of 82 
 
Confidential    
   
 contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for 
the duration of the study.  
5.8 Treatment Compliance  
Study t reatment compliance during the treatment period will be assessed via a patient diary and 
at all specified visits  in person . The Investigator,  or assigned  designee , will perform drug 
accountability and dosing compliance calculations for all study drugs (number of capsules that 
should have been taken versus actual number taken as evidenced by [CONTACT_209074] ) at Days 7 , 14, 21 
and 28 (end of treatment ). Overall dosing compliance is defined as taking between 80% and 
120% of the scheduled doses  for the period of time that the subject participates in the study .   
5.9 Packaging and Labeling  
Rayaldee (CTAP101 Capsules)  and matching placebo capsules will be prov ided in white, round, 
wide -mouth,  high-density polyethylene  (HDPE ) bottles with aluminum heat-induction safety 
seals with white, polypropylene, child -resistant (push down and turn) caps , [ADDRESS_249876] identification, investigational 
use caution statement s, storage conditions  and instructions for use.   
5.10 Storage and Accountability  
Rayaldee (CTAP101 Capsules)  and matching placebo capsules will be shipped to each site using 
standardized shipment and temperature monitoring procedures.  While at the study site, study 
drug will be stored at  controlled room temperature  (20-25°C or 68-77°F) with excursions 
allowed to 15°C to 30°C (59°F to 86°F), and protected from light and heat per label instructions  
in the supplied packaging, with access granted to authorized personnel only.  A temperature log 
recording the daily storage temperat ures will  be maintained at the sites. Accountability for all 
study drug s, from receipt until final reconciliation and return of drug by [CONTACT_149267], 
will be the responsibility of the investigator or the assigned designee(s).  In the case of 
temperature e xcursions, products should not be dispensed and the investigator or the assigned 
designee(s) should contact [CONTACT_209075].  
The investigator or assigned designee(s) will maintain study drug accountability records 
throughout the course of the study. A study drug accountability and dispensing log will record 
the study drug disposition. Each  site's overall  inventory of study drug supplies will be verified 
periodically  throughout the course of the study. All opened and unopened bottle s of study drug  
capsules  including subject returns are to be retained at each site until the sponsor  or designee has 
performed a complete accountabilit y, following which study drug will be returned to the sponsor  
or designee.  
5.[ADDRESS_249877] Retention at Study Site s 
At the conclusion of the study, a final accountability  will be performed by [CONTACT_093] (or 
designee) and verified by [CONTACT_10184]. Any discrepancies identified will be indicated, with CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 33 of 82 
 
Confidential    
   
 a specific explanation of each discrepancy. The investigator (or designee) must return all unused 
medication in accordance with the  sponsor’s instructions, and a copy of the clinical supplies 
return documentation will be returned to the sponsor  or designee. Drug accountability records, 
clinical drug supply receipts, and return  records  must be maintained by [CONTACT_093].  
5.12 Blinding  
All subjects , study personnel and the sponsor (and its designee s, with the exception of unblinded 
member (s) of the DSMB  and/or data management team ) will be blinded as to whether a given 
subject is in the Rayaldee (CTAP101 Capsules)  or placebo treatment group until after database 
lock or until the decision to break the blind is determined (eg, as a result of an emergent event).   
When the investigator determines that knowledge of treatment group assignment is required for 
medical man agement of an individual subject, the blind for the subject will be broken using the 
IRT system  in accordance with sponsor instructions .      
Further, all subjects , study personnel and the sponsor (and its designees, with the exception of 
unblinded member( s) of the DSMB and/or data management team)  will be blinded to serum total 
25D and  laboratory data obtained during treatment  until 
after database lock .   
Final unblinded site-specific data will be provided to the study sit es  within 3 months of 
finalizing the clinical study report . 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249878] or their legally 
authorized representative ( LAR ) will be permitted time and op portunity to inquire about details 
of the study and to decide whether or not to participate. The subject or their LAR  will receive a 
copy of the signed and dated consent form  and any written information provided to the study 
subjects  in a format (digital or hardcopy) that is safe and prevents infection . If any material 
change occurs that affects the conduct of the study  or the subject’s willingness to participate in 
the study , the subject or LAR will be required to sign an updated con sent form.  
The investigator or his/her designee will explain the nature of all aspects of the study to the 
subject  and/or their LAR , and answer all questions regarding this study, prior to obtaining 
informed consent.  
The process for obtaining consent will be in accordance with all applicable regulatory 
requirements. The subject or his/her  LAR and the investigator or his/her designee must both sign 
and date the ICF before the subject can participate in the study. The original ICF  (digital or 
hardcopy) will b e retained in the site study records. The investigator or his/her designee will 
ensure documentation of the consent discussion is in the subject’s medical record/source 
document. The decision by [CONTACT_209076] . The 
investigator or designee must emphasize to the subject that consent regarding study participation 
may be withdrawn at any time without penalty or loss of benefits to which the subject is 
otherwise entitled.  
If the ICF or patient information is amende d during the study, the investigator must follow all 
applicable regulatory requirements pertaining to approval of the amended ICF by [CONTACT_5030] /Ethics Committee  (IRB /EC) and use of the amended form (including 
ongoing subjects).  
6.2 Medical History  and Concomitant Medications  
A medical history , including demographics and concomitant medications , will be recorded at the 
screening  visit (Visit 1). Any symptom related to COVID -19 that started prior to initial dose, 
does not need to be reported a s medical history. Concomitant medications will be recorded at 
each additional study visit.  
6.3 Brief Physical Examinations and Vital Signs   
Brief PE and assessments  of VS (to include height, weight and BMI) and COVID -[ADDRESS_249879] is verified to 
be infected  with SARS -CoV -2.  Evaluations are presented in  Table 1.  Routine monitoring of VS 
and ongoing assessment s of COVID -19 disease severity will be performed at subsequent visits.  
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 35 of 82 
 
Confidential    
   
 Table 1 Evaluations  
Physical Examination s: Brief  PE.  
Vital Sign Measurements:  
 
 
 
 Height,  weight and BMI determination at screening visit (Day -3 to 0) 
and weight and BMI determination using screening height at the end of 
the treatment period ( Visit 5/ Day 28 +2). Blood pressure , heart and 
respi[INVESTIGATOR_697], temperature  and oxygen saturation (pulse oximetry)  will 
be measured and recorded after the subject has been sitting for at least 2 
minutes prior to any scheduled blood draws  at every  visit.  
Electrocardiogram (ECG)  
 ECG will be performed at screening visit (Day -3 to 0), Visit 3 (Day 
14±2) and Visit 5 (Day 28 +2), 
COVID -19 Severity and Quality -
of-life Assessments:  On each day during the study, subjects will  record once daily  at bedtime  
the severity of COVID -19 symptoms and quality -of-life using the FLU -
PRO  Plus© questionnaire.  
6.[ADDRESS_249880] immune status and vitD metabolism.  
All serum  calcium values will be adjusted for serum albumin  level of <4.0 g/dL.  
All clinically significant abnormal labora tory values should  be recorded as AEs and the 
investigator will follow -up (FU) according to Section 6.7.6  Clinical Significance . 
Subjects will be in a seated or supi[INVESTIGATOR_2526].   CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249881] of Laboratory Tests  
Hematology:  
Hematocrit  
Hemoglobin  
Platelet count  
Red blood cell count  
White blood cell count  
Peripheral blood neutrophils  
Peripheral mononuclear monocytes  
 
Serum b -hCG Pregnancy Test (only for females  of 
childbearing potential, defined as either not surgically sterile 
or not diagnosed as  postmenopausal )1 
 
Biomarkers , PD and PK parameters : 
 
Plasma  iPTH  
Serum total 25-hydroxyvitamin D (25D ) (blinded) * 
 
 
 
 
 
  
 
*Data will not be available until after database lock.  
 
  Serum Chemistry:  
Albumin  
Alkaline phosphatase  
Alanine aminotransferase  (ALT)  
Aspartate aminotransferase  (AST)  
Blood urea nitrogen  
Total c alcium ( corrected)  
Carbon dioxide  
Chloride  
Creatinine  
Estimated glomerular filtration rate (eGFR)[ADDRESS_249882] (only for females of 
childbearing potential, defined as either not 
surgically sterile or not diagnosed as 
postmenopausal)  
 
6.4.2 Sample Collection, Storage, and Shippi[INVESTIGATOR_209047] (unless the investigator considers the 
sample necessary for subject safety) and should be noted as “not done ” in source documentation 
along with a reason.   
A central laboratory experienced in clinical research trials will be utilized. Collect ion, 
processing, storage and shippi[INVESTIGATOR_209048]. Any d etailed instructions will be provided 
                                                 
[ADDRESS_249883].  
2 Calculated value.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249884] during the course of the study. 
This volume will include overage/backup volume  as described  in the study laboratory manual.  
Additional blood draws may be needed for unscheduled or repeat visits.  Every effort has been 
made to minimize the total amount of bl ood to be drawn.  Samples are to be shipped to the central 
laboratory for each subject as visits are completed.  
6.4.3 Clinical Supplies  
All supply vacutainers, blood collection tubes, needles, pi[INVESTIGATOR_6343], labels, boxes with labels for 
storage of serum and plasma s amples  and all necessa ry shippi[INVESTIGATOR_149222]/containers will be 
supplied by [CONTACT_779]. The site will supply all phlebotomy and centrifugation equipment including 
biohazard and/or safety supplies. The investigator will ensure that all biohazard wastes are 
disposed of in accordance with investigator site standard operating procedures ( SOPs ) and local 
regulations.  
6.[ADDRESS_249885]  (or 
designated site personnel)  will obtain the study drug assignment s for each subject and dispense 
the appropriate number of containers/ capsules , which  will be recorded i n the  drug accountability 
records . Study drug will be shipped to the subject’s home after confirmation of randomization , or 
if appro priate and feasible under current site access procedures, study drug can be dispensed 
directly to subjects or hand -delivered by [CONTACT_209077], as 
needed . 
All subjects , study personnel and the sponsor (and its designees , with the exception of unblinded 
member(s) of the DSMB and/or data management team ) will be blinded to treatment and serum 
total 25D  and data until the last subject comp letes the study  
and the data have been locked.  
6.[ADDRESS_249886] (DSMB)  
A five-member DSMB will be established which will be comprised of an expert in viral disease 
pathogenesis, a nephrologist who routinely treats patients with vitD repletion therapi[INVESTIGATOR_014] , a 
statistician  and a pulmonary medicine ex pert.  The DSMB will also include an unblinded safety 
monitor to identify potential safety hazards (eg, hypercalcemia ) in order to maintain blinding of 
treatment assignment and ensure study integrity. The DSMB will meet by [CONTACT_209078] 
3-4 weeks or  at the Committee’s discretion. Meetings may occur more often should serious 
adverse events (SAEs) or other safety issues arise. Specific responsibilities and activities of the 
DSMB will be defined in the DSMB charter.   CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249887] regardless of its causal 
relationship to study treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding or symptom  deemed clinically s ignificant ) or disease 
temporally associated with the use of a medicinal product whether or not considered related to 
the medicinal product.  
6.7.[ADDRESS_249888] 
any AE in detail in the source document and on the appropriate electronic case report form 
(eCRF ) including the date of onset, description, s everity, duration, relationship of the AE to the 
investigational study drug, action(s) taken and outcome. AEs, whether in response to a query, 
observed by [CONTACT_8786], or reported spontaneously by [CONTACT_209079].    
6.7.[ADDRESS_249889]’s participation in the study ends.  Adverse events that 
occur after the ICF has been signed but prior to the initiation of study drug will be captured as 
medical hist ory. Serious adverse events that occur after the ICF has been signed must be reported 
to the sponsor (as per protocol Section  [IP_ADDRESS] ) and will be documented in the source document 
and followed to a satisfactory resolution, until the investigator deems the event to be chronic or 
the subject to be stable, or until the subject ’s participation in the study ends.  
New or changes in COVID -19 symptoms are expected over the course of the COVID -19 
infection and should not be reported as AEs unless intervention was required or in the opi[INVESTIGATOR_209049].  All COVID -19 SAEs should be 
reported regardless.  
Information to be collected includes description  of the event  (event term) , date of onset, date of 
resolution, investigator -specified assessment of severity and relationship to the inves tigational 
study drug, seriousness, action taken with study drug (if applicable), as well as any required 
treatment or evaluations and outcome.  
AEs resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent 
medications,  or progression of disease states must be documented as AEs.  Pre-existing 
conditions (present before the start of the AE collection period) are considered concurrent 
medical conditions and should NOT be recorded as AEs, but must be documented in the medica l 
history section of the eCRF and in the source document. However, if the subject experiences a 
clinically significant worsening or complication of such a concurrent condition  (eg, pneumonia) , CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 39 of 82 
 
Confidential    
   
 the worsening or complication should be recorded as an AE. Inve stigators should ensure that the 
AE term recorded captures the change in the condition.  
Each AE should be recorded to represent a single diagnosis. Accompanying signs or symptoms 
should NOT be recorded as additional AEs. If a diagnosis is unknown, then sign(s) or 
symptom(s) should be recorded as an AE(s). Changes in laboratory values  are judged to be 
clinically significant if some action or intervention is required or if the investigator judges the 
change to be beyond the range of normal physiological fluct uation. If abnormal laboratory values 
are the result of pathology for which there is an overall diagnosis, the diagnosis only should be 
reported as an AE.  
Pre-planned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to the start of AE 
collection are not considered AEs. However, if a pre -planned procedure is performed early (eg, 
as an emergency) due to a worsening of the pre -existing condition, the worsening of the 
condition should be captured as an AE. Elective procedures performed wher e there is no change 
in the subject’s medical condition (including thought processes around the reason for the elective 
procedure) should not be recorded as AEs, but should be documented in the subject’s source 
document and captured in the eCRF as procedur es. 
Any report of pregnancy identified for any female subject or for a female partner of a male  
subject should be reported immediately (within 24 hours of being informed) by [CONTACT_209080] 24 hours of awarenes s to 
[EMAIL_4074] . 
Pregnancies will be considered ‘events of special interest’ and will not be captured as serious  
adverse events (SAEs). Investigators should follow specific procedures for reporting them to  
OPKO Pharmacovigilance. Pregnancies will be followed to termination or six weeks post -
delivery  for determination of resolution to the event. Subjects who become pregnant during  
treatment must immediately be withdrawn from study drug treatment . 
The Medical Dictionary for Regulatory Activities  (MedDRA), Version 23.0 or later, will be used 
to code all AEs.  
6.7.4 Severity  
The intensity of the AE will be rated by [CONTACT_941] i nvestigator per Common Termin ology C riteria for 
Adverse Events  (CTCAE ), Version 5.0 . 
It should be noted that the clinical severity and seriousness of an AE are not synonymous, eg , a 
severe headache is not classified as serious until it meets the required elements as an SAE.  
The maximum severity attained for each AE reported will be recorded in the eCRFs.   
6.7.5 Relationship  
The investigator’s assessment of an AE's relationship to the investigational study drug  is not a 
factor in determining whether the AE is reported in the AE section of the eCRF. If there is any 
doubt as to whether a clinical observation is an AE, the event should be reported.   
The relationship or association of the study drugs in causing or contributing to the AE will be 
characterized by [CONTACT_209081] 3. 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 40 of 82 
 
Confidential    
   
 Table 3  Adverse Event Relationship Criteria  
Relationship  Criteria  
Not related  • The temporal sequence of the AE onset relative to administration of the investigation al 
product is not reasonable.  
• Disease or other drugs provide plausible explanations.  
• Dechallenge (if performed) is negative or ambiguous.  
Unlikely related  • The temporal sequence of the AE onset relative to the administration of the investigational 
product is reasonable.  
• Could also be explained by [CONTACT_19699].  
• Dechallenge (if performed) is positive or uncertain.  
• Rechallenge is negative.  
Possibly related  • The temporal sequence of the AE onset relative to administration of the investigational is 
reasonable.  
• Unlikely to be attributed to disease or other drugs.  
• Dechallenge (if performed) is positive.  
Related  • The temporal sequence of the AE onset relative to administration of the investigational 
product is reasonable.  
• Cannot be explained by [CONTACT_19699].  
• Dechallenge (if performed) is positive and pharmacologically/ pathologically plausible.  
• Rechallenge (if feasible) is positive.  
• The AE shows a pattern consistent with previous knowledge of the investigational product 
or product class, i.e., pharmacologically or phenomenologically recognized/plausible or an 
objective and specific medical disorder.  
6.7.6 Clinical Significance  
Changes in unblinded laboratory values , vital signs  or other diagnostic procedure  
outcomes/results are only considered to be AEs if they are judged to be clinically significant (ie, 
if some intervention or therapy is required or if the investigator judges the change to be beyond 
the expected variation).  Any abnormalities will automatically be considere d clinically 
significant unless the investigator indicates not clinically significant directly on the laboratory 
paperwork  or source documentation . 
6.7.7 Serious Adverse Events  
[IP_ADDRESS]  Definition  
An SAE is defined by [CONTACT_209082] g an investigati onal 
study that result in any of the following outcomes:  
• Death  
• Life-threatening AE  
• Hospi[INVESTIGATOR_1081]  
• A persistent or significant disability (substantial disruption of the ability to conduct normal 
life functions)/incapacity  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 41 of 82 
 
Confidential    
   
 • A congenital anomaly/birth defect  
• Important medical events that may not result in death, may be life threatening, or may require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, 
they may jeop ardize the subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, bloo d 
dyscrasias or convulsions that do not result in subject hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse.    
Research subjects will be instructed to notify the research center for any emergent condition and 
will be given the emergency contact [CONTACT_149276].  
[IP_ADDRESS]  Expectedness  
SAEs must be assessed as to whether they were expected to occur or unexpected, meaning not 
anticipated based on current knowledge about the investigational compound found in the 
proto col or Investigator Brochure (IB) for Rayaldee (CTAP101 Capsules) .  Categories are:  
• Unexpected  - nature or severity of the event is not consistent with the product information ; 
• Expected - event is known based on the product information.  
[IP_ADDRESS]  Reporting Serious Adverse Events  
Any AE considered serious by [CONTACT_209083] [ADDRESS_249890]: OPKO Pharmacovigilance  
Fax:  
E-mail:   
The IRB/IEC should be made aware according to currently prescribed institutional guidelines.  A 
written report should be provided consist ing of the SAE Form  and other necessary source 
documents. If the subject is hospi[INVESTIGATOR_45891], then the 
investigator should attempt to obtain a copy of the hospi[INVESTIGATOR_209050], and provide them to the sponsor  or designee as soon as possible.  
For any information not available at the time of the first report that becomes available lat er, the 
investigator should update the SAE Form and eCRFs and provide any additional documentation 
to OPKO Pharmacovigilance  and IRB/IEC within 1 working day of receipt.  
The sponsor  or designee will notify the appropriate regulatory agencies of any serious and 
unexpected SAEs associated with the use of the investigational study drug according to 
regulation s. Copi[INVESTIGATOR_209051]/EC. 
If using a local IRB /EC, the investigator is responsibl e for informing his or her IRB /EC per its 
requirements of any SAEs at that site. Copi[INVESTIGATOR_149225] /EC, 
regulatory authorities, and other physicians must be provided to the Study Contact .  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249891] concomitant medication history (previous three 
months) in the source document and eCRF.   
6.9 Removal of Subjects from the Study  or Study Drug  / Stoppi[INVESTIGATOR_209052]  a subject from study drug  treatment for any of the following 
reasons:  
• A major protocol deviation occurs ;  
• A serious or intolerable AE occurs ; 
• The subject has a confirmed pregnancy;  
• A clinically significant change in a laboratory parameter occurs  (eg, increase in s erum 
calcium above upper limit allowed) ; and, 
• A clinically significant change in ECG at Visit 3 occurs as compared to baseline (eg, 
prolongation of QT interval) . 
The investigator may withdraw a subject from the study for any of the following reasons:  
• The s ubject requests to be discontinued from the study  (withdraws consent) ; or, 
• The subject is lost to follow -up. 
Subjects who develop severe (CTCAE ≥ 3) abnormalities (low or high) of serum phosphorus, 
uric acid or plasma iPTH will be withdrawn from study drug  treatment.  
Enrollment of subjects into the study will be paused if mortality in the treatment arm is ≥ 7% 
higher compared to the placebo arm until the DSMB makes an assessment about causality, and 
may resume once the DSMB deems it acceptable to continue ( if applicable).  
No subject replacement is planned.  All subjects withdrawn from treatment will continue in the 
study until study completion and perform all assessments unless consent is withdrawn. The 
investigator will be requested to make all reasonable e fforts to obtain clinical status at FU.   
6.10 Appropriateness of Measurements  
The safety and tolerability of Rayaldee (CTAP101 Capsules)  will be determined by [CONTACT_209084], serum  25D, calcium (corrected for serum albumin) and phosphorus , and  eGFR .    CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 43 of 82 
 
Confidential    
   
 7 STUDY ACTIVITIES  
7.1 Screening and Randomization  (Visit 1/ Day -3 to 1) 
7.1.1 Screening (Day -3 to 0)  
Visit to occur within [ADDRESS_249892] for SARS -CoV -2 infection .  
• Review study ICF (A signed ICF will be obtained from each subject prior to any study -related 
procedures) . 
• Review of inclusion/exclusion criteria . 
• Medical history and demographics . 
• Review of prior medications  (previous three months) . 
• Brief PE. 
• VS assessment  (weight, height and BMI) . 
• ECG.  
• Blood samples will be obtained  for the following:  
o Hematology, serum chemistry (full panel and eGFR determination)  (see Table 2);  
o Serum b -hCG pregnancy test (for females of childbearing potential);  
o  
o Plasma iPTH and serum 25D ; and, 
o  
• Training provided on study drug dosing, storage and use.  
• Diary instructions provided for assessment activities. Subject will be trained to assess and 
record in the diary AT VISIT the severity of COVID -19 symptoms and quality -of-life using  
the FLU -PRO  Plus© questionnaire . 
• Subject will assess and record in the diary at bedtime  the severity of  COVID -19 symptoms 
and quality -of-life using the FLU -PRO  Plus© questionnaire . 
7.1.2 Randomization and Initial Treatment  (Day 1)  
• Day [ADDRESS_249893] on the day of randomization.  
• If qualified, s ubject s will be randomized to t reatment with active or placebo study drug 
following receipt and review of laboratory test results . Study drug will be shipped to 
subject’s home  or if appropriate and feasible under current site access procedures, study drug 
can be dispensed directly to subjects or hand -delivered by [CONTACT_209085], as needed .  
• Subject will self-administer [ADDRESS_249894] 3 hours after administration of study drug .  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 44 of 82 
 
Confidential    
   
 7.2 Days 2 -6 
• No study site visits . 
• On each of Days [ADDRESS_249895] 3 hours after administration of study drug . 
• From Day [ADDRESS_249896] 3 hours after administration  of 
study drug . 
• Subject s will assess and record in the diary  each day at bedtime the severity  of COVID -19 
symptoms and quality -of-life using the FLU -PRO  Plus© questionnaire . 
7.3 Visit 2 (Day 7  ± 2) 
Activities to be performed during site visit:  
• Review of concomitant medications . 
• AE assessment . 
• VS assessment . 
• Blood samples will be obtained  for the following:  
o Hematology, serum chemistry (full panel and eGFR Determination)  (see Table 2); 
o  
o Plasma iPTH and serum 25D;  and, 
o  
• Urine pregnancy test for females of childbearing potential (a positive test result will be 
confirmed with a serum b -hCG test).  
• Study d rug reconciliation/compliance review with subject (study d rug returned to subject 
after visit review).  
• Diary review with subject . 
• Subject will self -administer [ADDRESS_249897] 3 hours after 
administration of study drug.  
• Subject will assess and record in the diary at bedtime  the severity  of COVID -19 symptoms 
and quality-of-life using  the FLU -PRO  Plus© questionnaire . 
7.4 Days 8 -13 
• No study site visits . 
• Subject will self -administer [ADDRESS_249898] 3 hours after administration of study drug.  
• Subject will assess and record in the diary each day at bedtime  the severity  of COVID -19 
symptoms using  the FLU -PRO  Plus© questionnaire . CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 45 of 82 
 
Confidential    
   
 7.5 Visit 3 (Day 14  ± 2) 
Activities to be performed during site visit:  
• Review of concomitant medications . 
• AE assessment . 
• VS assessment . 
• ECG (prolonged QT -interval will be referred to a Cardiologist for review).  
• Blood samples will be obtained  for the following analyses:  
o Hemat ology, serum chemistry (full panel and eGFR determination ) (see Table 2);  
o  
o Plasma iPTH and serum 25D;  and, 
  
• Urine pregnancy test for females of childbearing potential (a positive test result will be 
confirmed with a serum b -hCG test).  
• Study drug reconciliation/compliance review with subject (study drug retur ned to subject 
after visit  review ). 
• Diary review with subject . 
• Subject will self -administer [ADDRESS_249899] 3 hours after administration of study drug.  
• Subject will assess and record in the diary at bedtime  the severity  of COVID -19 symptoms  
and quality -of-life using  the FLU -PRO  Plus© questionnaire . 
7.6 Days 15 -20 
• No study site visits.  
• Subject will self -administer [ADDRESS_249900] 3 hours after administration  of study drug.  
• Subject will assess and record in the  diary each day at bedtime the severity of COVID -19 
symptoms and quality -of-life using the FLU -PRO  Plus© questionnaire.  
7.7 Visit 4 (Day 21  ± 2) 
Activities to be performed during site visit:  
• Review of concomitant medications.  
• AE assessment.  
• VS assessment.  
• Blood samples will be obtained  for the following analyses:  
o Hematology, serum chemistry (full panel and eGFR determination) (see Table 2);  
o  
o Plasma iPTH and serum 25D;  and, CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 46 of 82 
 
Confidential    
   
 o  
• Urine pregnancy test for females of childbearing potential (a positive test result will be 
confirmed with a serum b -hCG test).  
• Study drug reconciliation/compliance review with subject (stud y drug returned to subject 
after visit review).  
• Diary review with subject.  
• Subject will self -administer [ADDRESS_249901] 3 hours after administration of study drug.  
• Subject will self -assess and record in the diary at bedtime  the severity  of COVID -19 
symptoms  and quality -of-life using the FLU -PRO  Plus© questionnaire . 
7.8 Days 22 -27 
• No study site visits . 
• Subject will self -administer [ADDRESS_249902] 3 hours after a dministration of study drug.  
• Subject will assess and record in the diary each day at bedtime the severity of COVID -19 
symptoms and quality -of-life using the FLU -PRO  Plus© questionnaire.  
7.9 Visit 5 (Day 28 + 2) (End of Treatment /Early Termination ) 
Activities to be performed during site visit:  
• Review of concomitant medications.  
• AE assessment.  
• VS assessment  (weight and BMI) . 
• Brief PE. 
• ECG (prolonged QT -interval will be referred to a Cardiologist for review).  
• Blood samples will be obtained  for the following analyses:  
o Hematology, serum chemistry (full panel and eGFR determination) (see Table 2);  
  
o Plasma iPTH and serum 25D;  and, 
o  
• Urine pregnancy test for females of childbearing potential (a positive test result will be 
confirmed with a serum b -hCG test).  
• Study drug reconciliation/compliance review with subject (treatment complete – no further 
study drug dispensed).  
• Diary review with subject.  
Subject will assess and record in the diary at bedtime  the severity  of COVID -19 symptoms using  
the FLU -PRO  Plus© questionnaire .  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 47 of 82 
 
Confidential    
   
 7.10 Days 29 -41 
• No study site visits.  
• Subject will assess and record in the diary each day at bedtime the severity of COVID -19 
symptoms and quality -of-life using the FLU -PRO  Plus© questionnaire . 
7.11 Visit 6 (Day 42 ± 4  (Follow -up – Telephone Visit) ) 
• Upon awakening in the morning, subject will assess and record in the diary  the severity of  
COVID -19 and quality -of-life using the FLU -PRO  Plus© questionnaire . 
Subject will self -report via telephone to site staff:  
• Review of concomitant medications.  
• AE assessment.  
• Diary review with subject.  
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 48 of 82 
 
Confidential    
   
 8 QUALITY CONTROL AND ASSURANCE  
The study will be  conducted in accordance with the protocol, ICH/GCP (International Co uncil 
for Harmonisation [ICH] and Good Clinical Practice [GCP ]), and applicable SOP s and 
regulation s, to ensure that the safety and welfare of subjects are addressed, and to confirm that 
problems reported by [CONTACT_149279]. Verification of study documents and activities 
(if applicable) will be conducted to confirm accuracy of recorded data and its analysis.  Audit 
observations and findings will be documented and communicated to appropriate study personnel 
and management. An inspection may be conducted by [CONTACT_12721]. The investigator 
must allow direct access to study documents dur ing these inspections and audits.  
Monitoring visits (on site and/or remote) will evaluate study conduct, data integrity, protocol, 
and GCP compliance. The investigator is responsible for the accuracy, completeness, legibility, 
and timeliness of the data reported. All source documents are to be completed in a neat, legible 
manner to ensure accurate interpretation of data.  Source documents and laboratory repo rts will 
be reviewed to ensure that they are accurate and complete.  Any issues arising from these reviews 
will be communicated directly to the investigator in the monitoring report with recommendations 
for any Correct ive and Preventive Action  plans. The DS MB will be apprised of any serious 
continuing non -compliance.  
To ensure the quality of the clinical data across all subjects, a Clinical Data Management review 
will be performed by [CONTACT_45584] M anager or designee on subject data entered or integrated into the 
electronic data capture ( EDC ) system.  During the review, subject data will be checked for 
consistency, omissions, and any apparent discrepancies. In addition, the data will be reviewed for 
adherence to the protocol, and ICH/GCP.  To resolve any questions  arising from the Data 
Management review process, data queries and/or data clarification notifications will be generated 
via the EDC system for completion and resolution.  
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 49 of 82 
 
Confidential    
   
 9 PLANNED STATISTICAL METHODS  
9.1 General Considerations  
All analyses  will be performed u sing SAS® or other appropriate s tatistical software . All data 
collected on eCRFs , diary (from ePRO)  and from clinical laboratory evaluations will be grouped 
and listed by [CONTACT_209086]-group , subject, visit, date and time as feasible. Summary tables will 
be presented by [CONTACT_209087]. Descriptive summaries of categorical outcomes will 
include the proportion  of subjects. Descriptive summaries of quantitative measures will include 
the number of subjects, mean, standard deviation ( SD), median, minimum, and maximum or as 
appropriate. In descriptive summary tables, if needed, the geometric mean will be calculated as 
the nth root of the resulting product of the values, and  the coefficien t of variation (in percent, 
%CV) will be calculated as 100* (SD/[arithmetic mean]).  
Arithmetic means, SDs, medians, and geometric means will be reported with two significant 
figures more than  the reported values. Minimum and maximum values will be reported with the 
same accuracy as the reported source data. The %CV will be rounded to [ADDRESS_249903] calculations will be based on the number of subjects in 
the sub-group  and selected population unless otherwise specified.   
In the event there are multiple results at a given visit and/or time  point, the following logic will 
be applied for purposes of summarization by [CONTACT_149281]: for pre -dose measureme nts and 
selection of a baseline value, the more recent non -missing result will be used, preferably the 
result recorded on Day 0 (the day prior to first administration of study drug), if available ; for 
post-dose measurements, the earliest of the results wil l be selected. If multiple laboratory results 
are available for the same date and time and the discrepancy could not be resolved, then the 
arithmetic mean of the results could be used unless specified in the data management plan or data 
handling convention s finalized before breaking the study randomization blind. All subjects 
entered into the clinical database will be included in subject data listings.  
Specific analysis details will be provided in the Statistical Analysis Plan.   
9.2 Missing Data  
For the primary endpoint based on achievement of serum 25D level ≥50 ng/mL  at Day [ADDRESS_249904] day of achieving a score of ≤ 5 and followed by [CONTACT_8622] 5 
days with score ≤5, as defined in Section 9.10.[ADDRESS_249905] day of achieving a score of ≤ 5, and followed by [CONTACT_8622] 5 days CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 50 of 82 
 
Confidential    
   
 with score ≤5 , provided that no individual score is ≥1,  as defined in Section 5.[ADDRESS_249906] day of achiev ing a score of ≤1 and followed by [CONTACT_8622] 5 days with score ≤1, 
as defined in S ection 9.10.[ADDRESS_249907] and the SAS MIANALYZE procedure will be used to 
generate valid statistical inferences by [CONTACT_31571] 50 analyses using Rubin’s 
formula. N o other efficacy data will be imputed.  
The secondary endpoints based on incidence will not be imputed.  These endpoints, for example 
hospi[INVESTIGATOR_209053], will either occur, or will be assumed not to have 
occurred.  Since these items r equire clinical care, the occurrence will unlikely go unreported.  If 
there are more than 10% of subjects who are truly missing and lost to follow up, a tippi[INVESTIGATOR_209054], first assuming that none of the events occurred in the missing sub jects, 
and then if all missing subjects had the event.  If there is a difference based on these extremes, 
the number of missing subjects assumed to have the event will be increased by 2 in the treated 
group, while holding the incidence in the placebo group  as observed, until the tippi[INVESTIGATOR_209055].  Missing values from the quality of life components of FLU -PRO Plus© questionnaire will 
not be imputed.  The analysis of these items will be based on observed cases only  with resolution 
requiring at least a three -day duration .   
AEs with missing onset date will be treated as TEAEs and missing onset date will be imputed as 
Day 1, unless the event end date indicates that the event resolved prior to the administration of 
the investigational study drug.  In this case, it will be documented in medical history. AEs with 
partial onset date will similarly be treated as TEAEs unless the partial onset date or end date of 
the event is complete enough to indicate that the event started or resolved prior to the 
administrat ion of the investigational study drug, in which case it will be documented in medical 
history.  
If an AE has missing severity or relationship to study drug, the missing severity will be set to 
severe and the missing relationship will be set to Related in al l summary tables.  
For the purpose of inclusion in prior or concomitant medication tables, incomplete medication 
start and stop dates will be imputed and then categorized into prior or concomitant medication 
categories.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 51 of 82 
 
Confidential    
   
 9.3 Planned Data Safety Monitoring :  
A five-member DSMB will be established which will be comprised of an expert in viral disease 
pathogenesis, a nephrologist who routinely treats patients with vitD repletion therapi[INVESTIGATOR_014] , a 
statistician  and a pulmonary medicine expert. The DSMB will also include an  unblinded safety 
monitor to identify potential safety hazards (eg, hypercalcemia) in order to maintain blinding of 
treatment assignment and ensure study integrity. The DSMB will meet by [CONTACT_209078] 
3-4 weeks or at the Committee’s discretion. Meet ings may occur more often should serious 
adverse events (SAEs) or other safety issues arise. issues. Specific responsibilities and activities 
of the DSMB will be defined in the DSMB charter.  
9.4 Determination of Sample Size  
Primary outcome #1 (attainment of se rum 25D levels at ≥50 ng/mL):  Assuming that no more 
than 25% of the control group will achieve an increase in serum 25D to ≥50 ng/mL by [CONTACT_2006] 28 
versus greater than 75% in the CTAP101 Capsules group, a sample size of 19 per group will 
provide 90% power at a lpha 0.[ADDRESS_249908] of the two groups.    
Primary outcome # 2 (severity  of illness  by [CONTACT_209088] ): A sample size of 80 per group (total 
of 160) is planned.  This will provide greater than 80% power at one sided alpha of 0.[ADDRESS_249909] assuming 50% of subjects in the control group and 70% of the CTAP101 
Capsules  group will have achieved resolution of symptoms by [CONTACT_2006] 28.  This is based on an 
expected hazard ratio (of achieving  resolution) of 1.74.   
9.5 Analysis Populations  
The intent -to-treat (ITT) populat ion will include all randomized subjects .   
The full analysis set (FAS) or population is a subset of the ITT set from which subjects are 
excluded who did not receive any study dr ug or have a baseline aggregate five symptom score of 
≤5.  For the secondary analyses of individual symptom scores and quality -of-life responses, 
further subjects who do not have a baseline score of >[ADDRESS_249910] a major protocol deviation prior to resolution 
of the aggregated five symptoms , will also be used as supportive evidence of efficacy.  Subjects 
who are non -compliant with the requirements of the protocol after achieving resolution of the five 
COVID -19 symptoms will be included in the PP set due to the expectation that such subjects will 
likely discontinue prematurely from the study.  
The safety population includes all subjects who received any amount of stu dy treatment and will 
be the population for safety  evaluations .   CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249911] characteristics, including age, sex, race, ethnicity, 
height, weight , BMI  and eGFR  will be summarized by [CONTACT_30157] (CTAP101 Capsules and 
placeb o). Primary, secondary  outcomes will be summarized by [CONTACT_209089], using CONSORT guidelines to present descriptive statistics, including mean, 
median, standard deviation, quartiles, interquartile range, minimum, and maximum  values for 
subjects within the site, overall and by [CONTACT_1570]. Continuous variables will be 
summarized using means, standard deviations, and quartiles, while categorical variables will be 
summarized using frequencies and percentages.  
9.[ADDRESS_249912] characteristics, including age, sex, race, ethnicity, height, weight, BMI and 
eGFR, will be tabulated for the both the treatment and placebo control population. Age (years) 
will be calculated as (date of ICF - date of birth + 1)/365 , or as reported age (to the nearest 
month) at study entry if date of birth is not collected . 
9.[ADDRESS_249913] disposition will be tabulated and descriptively summarized for all randomized subjects 
by [CONTACT_209086]-group s separately and combined. The primary reason for premature study 
termination will be detailed together with the proportion  of subjects discontinuing for each 
reason. The primary reason for premature study termination  will be recorded .  
9.8 Prior and Concomitant Medications  
Prior medications are defined as any continuing or new medication used within 12 weeks  and 
discontinued before Visit  1. Concomitant medications are defined as any continuing or new 
medication taken from Visit  1 or anytime  thereafter until the end of the study. World Health 
Organization Drug  Dictionary Enhanced version September 201 7, Format C, or later will be used 
to code concomitant and prior medications. Prior and concomitant medications will be tabulated 
by [CONTACT_209086]-group . All medications recorded on the eCRF, including start and stop (or 
ongoing as of) dates, AE number (if applicable), indication, dose, unit, route, and frequency will 
be listed. For the purpose of inclusion in prior or concomitant medication tabl es, incomplete 
medication start and stop dates will be imputed and then categorized into prior or concomitant 
medication categories.  
9.9 Safety Analyses  
All subjects in safety population will be included in the safety analysis. Statistical summary 
analysis of  safety data will be descriptive and performed by [CONTACT_68400].  No inferential 
hypothesis testing will be performed on the safety variables with the exception of comparisons of 
serum calcium  and serum  phosphorus  between treatment groups .  
9.9.1 Adverse Events  
All AEs will be collected on the eCRF and coded via SOC and preferred term using MedDRA 
version 23.0 or higher.  Additionally , the intensity of all AEs will be coded using CTCAE v. 5.0 .  
AEs with missing onset date will be treated as TEAEs and missing onset  date will be imputed as 
the date of Visit  1, unless the event end date indicates that the event resolved prior to Visit  1, in CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 53 of 82 
 
Confidential    
   
 which case it will be documented in medical history. AEs with partial onset date will be treated 
as TEAEs unless the partial onse t date or end date of the event is complete enough to indicate 
that the event started or resolved prior to the administration of the investigational study drug, in 
which case it will be documented in medical history. Detailed information collected for each  
TEAE will include:  AE number, a description of the event, start date, end date or ongoing as of 
date, outcome, therapy for event, whether the AE is serious, seriousness criteria (life -threatening, 
death, hospi[INVESTIGATOR_059]/prolongation of hospi[INVESTIGATOR_059], co ngenital anomaly, persistent or 
significant disability/incapacity, required intervention to prevent permanent impairment/  
damage), severity, and relationship to the study drug. The incidence of the AEs will be 
summarized by [CONTACT_209086]-group  for all TEAEs, potentially drug -related TEAEs, serious 
TEAEs, discontinuation due to TEAEs, TEAEs by [CONTACT_8792]  (definite, probable, 
possible, unrelated) and TEAEs by [CONTACT_926] (mild, moderate, severe). The number and 
percentages of subject s with a TEAE will be summarized by [CONTACT_209090]-group . TEAEs will be sorted in descending order of 
total incidence of SOC and preferred term within each SOC. The percentages will be based on 
the number  of Safety  subjects in a particular population sub-group . If a subject has more than 
one TEAE that code to the same preferred term, the subject will be counted only once for that 
preferred term. Similarly, if a subject has more than one TEAE within a SOC c ategory, the 
subject will be counted only once in that SOC category. All AEs collected on the eCRF will be 
included in the listings. An additional listing of all subject deaths will also be provided.  
Diagnostic procedures will be collected  separately  in the eCRF and coded via SOC and preferred 
term using MedDRA version 23.0 or higher in a manner similar to AEs.  
9.9.2 Vital Signs  
Observed VS values will be summarized descriptively at Visit 1 and changes from baseline will 
be descriptively summarized by [CONTACT_209091] . Summaries will include n (%), 
mean, SD, median, minimum, and maximum . Vital sign values will be listed.  
9.9.3 Secondary Safety A nalyses  
Secondary safety endpoints for will include incidence of hypercalcemia and drug -related 
hyperphosphatemia.  The number (n, %) of subjects with  hypercalcemia (serum  calcium >10.5 
mg/dL) or hyperphosphatemia (> 4.5 mg/dL ) will be compared between study arms using a C hi-
square test statistic (alpha=0.05) .  
9.[ADDRESS_249914] of resolution of symptoms based on the aggregate FLU -
PRO Plus© symptom score will be performed only if the attainme nt of serum 25D levels ≥50 
ng/mL at Day 14 is significant at <0.025.   
The first primary efficacy endpoint, attainment of serum 25D levels at ≥50 ng/mL, will be 
assessed with a Chi -square statistic at Day 14. The serum 25D levels will also be compared 
betw een treatment groups at Days 7, 21 and 28 with a Chi -square statistic.   CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 54 of 82 
 
Confidential    
   
 The second primary efficacy endpoint is the time to resolution of symptoms, defined as a 
reduction in the aggregate  FLU -PRO Plus© scores recorded on Day 0 (prior to study drug 
initiation ) for the selected five COVID -[ADDRESS_249915] 
day of achieving the aggregate ≤[ADDRESS_249916] two successive qualifying scores which span a 
minimum of three consecutive days , provided tha t no score greater than 5 is recorded between 
the two qualifying scores . For clarity, resolution will be considered as having been achieved if 
two successive aggregate scores of ≤[ADDRESS_249917] two days (but not more than 5 days) later even if no score has been 
recorded between the two days.  Missing symptom score values will be handled as described in 
Section 9.2. The number of days to resolution will be analyzed with a  Cox proportion al hazards 
model with covariates (baseline aggregate FLU -PRO Plus© score for the selected five symptoms, 
baseline serum 25D, and body weight).  
As a sensitivity analysis of the resolution of symptoms, a tippi[INVESTIGATOR_209056], with no 
missing interval, followed by [CONTACT_209063] -day interval, 
that is, 1,  2, and 3 missing days between the two consecutive qualifying scores.  The duration of 
resolved days, assessed as achieving resolution for four, five, six or seven consecutive days 
without evidence of relapse, will be summarized by [CONTACT_1570].  
Subgroup analyses for the primary efficacy endpoints will be based on age (≤40  or >40 years), 
severity of the selected five COVID -19 symptoms at baseline ( aggregate FLU -PRO Plus© score 
of ≤  or > the median score ), attained serum 25D at Day 14 (below, within or above the targeted 
range of 50 to 100 ng/mL), body weight (≤100 or >100 kg), BMI (≤30 or >30), dosing compliance 
(<80% or ≥80%), gender, race, ethnicity, number of comorbidities (<1 or ≥1), duration of treatment 
(≤10 or >10 days) and prior or intercurrent COVID -19 vaccination and/or monoclonal antibody 
therapy for COVID -19.   
In addition, the number of days to resolution of the five aggregated symptoms will be compared 
based on the serum 25D level at Day 14 (<50  ng/mL vs 50 to 100 ng/mL and 50 to 100 ng/mL vs 
>100 ng/mL ), regardless of the assigned treatment group.  The compari sons will be done using a 
Chi-square test.  Frequency of relapses will be calculated, if possible, to account for potential 
worsening of symptoms after resolution (defined above), with relapse being defined as achieving 
an aggregate  score > 5 for a minimum of three consecutive days.   
9.10.2  Secondary Endpoints  
The following secondary endpoints will also be tested  statistically with methods described 
below, and the resulting nominal p -value will be reported for evaluation :   
1) The number of days to resolution of five symptoms (trouble breathing, chest congestion, 
dry or hacking cough, body aches and pains, and chills and shivering), as measured by 
[CONTACT_209062] -PRO Plus© questionnaire , with resolution defined as the first aggregate symptom 
score of ≤5 which is maintained for  a minimum of three consecutive days, with no 
individual symptom score >1 ;  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
CTAP101  | CTAP101 -CL-2014 | CTAP101 -CL-2014 Protocol 
VV-TMF -183735 | Version 8.0 dated 16 Nov 2021 
 
Protocol CTAP101 -CL-2014 OPKO Pharmaceuticals,  LLC 
CTAP101  (calcifediol) Extended -release  Capsules   Page 55 of 82 
 
2) Resolution, defined as the first score of ≤5 which is maintained for a minimum of three 
consecutive days (without subsequent relapse), for the aggregate five COVID-19 
symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and 
pains, and chills and shivering) and for each individual symptom, defined as a score of 0 
or 1, as measured by [CONTACT_209062]-PRO Plus© questionnaire as of Day 10; 
3) Incidence of emergency room/urgent care visits;  
4) Incidence of oxygen saturation below 94% (or requirement for supplemental oxygen);  
5) Incidence of hospi[INVESTIGATOR_602] (mean duration of hospi[INVESTIGATOR_209036]);  
6) Incidence of requirement for mechanical ventilation; and, 
7) Mortality rate (as incidence). 
Endpoints listed will be summarized. For the analysis of individual symptoms in endpoint #2 above, the threshold of ≤1 is appropriate because it describes minor symptom severity (at worst “a little bit”) which seems unlikely to presage a poor outcome. Analysis of the resolution of 
individual symptoms will be performed using a logistic regression, with baseline symptom score, 
baseline 25D level, and body weight as covariates. Analysis of the secondary endpoints based on incidence will be performed with a Chi-square test. Mean duration will be analyzed with 
analysis of covariance (ANCOVA). Mortality will be analyzed as incidence, with logistic 
regression with baseline symptom score, baseline 25D level and body weight as covariates. 
Rates only will be reported if there are too few deaths to be formally analyzed. 
The severity, duration and clinical course of COVID-19 illness will be compared between treatment groups by [CONTACT_209064]-of-life assessments recorded on the FLU-PRO 
Plus
© questionnaire. Five of the six items from the questionnaire to be analyzed are: : “Overall, 
how severe were your infection symptoms today?”, “Overall, how were your infection symptoms today compared to yesterday?”, “How much did your infection symptoms interfere 
with your usual activities today?”, “Have you returned to your usual activities today?”, “In 
general, how would you rate your physical health today?”, and “Have you returned to your usual 
health today?”  The scores for: symptom severity range from 0 (no infection symptoms today) to 
4 (very severe); symptoms today range from 1 (much better) to 7 (much worse); symptom 
interference range from 1 (not at all) to 5 (very much). The first of two consecutive scores of ≤[ADDRESS_249918] three days and no more than five days will be considered the day of resolution, 
provided that no intervening scores of >1 are recorded.  The scores for return to usual activities 
or health are either “yes” or “no”, and the first occurrence of “yes” will be deemed to be day of 
resolution provided that a second “yes” is recorded no more than 5 days later without an 
intervening “no”.  The remaining sixth item to be analyzed is: “physical health range from 1 
(poor) to 5 (excellent). The first of two consecutive scores of >[ADDRESS_249919] three days and 
no more than five days will be considered the day of resolution, provided that no intervening 
scores of <4 are recorded. Each item will be compared between treatment groups using a Cox 
proportional hazards model with covariates (aggregate FLU-PRO Plus
© score for the selected 
five COVID-19 symptoms at baseline, serum total 25D at baseline, and body weight). 
The clinical course of COVID-19 will be examined by [CONTACT_209065] 25D 
levels <50 ng/mL, 50 to 100 ng/mL and >100 ng/mL at Days 7, 14, 21 and 28. 
 
  
________________________________________________________________________________________________  
Confidential  
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 56 of 82 
 
Confidential    
   
   
   
  
  
  
  
  
  
  
   
  
 
 
  
  
   
   
 
 
   
 
  
 
 
 
 
 
 
 
 
 
 
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021

  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249920] /Ethics Committee  Approval  
GCP requires th at the clinical protocol, any protocol amendments, the IB, the ICF, and all other 
forms of subject information related to the study and any other necessary documents be reviewed 
by [CONTACT_149288] t Review Committee (eg, an IRB ). 
10.[ADDRESS_249921] of the Study  
In accordance with applicable country -specific regulations, the sponsor  will obtain approval from 
the appropriate regulatory authority(ies) prior to initiating the study in that country.  This study 
will be conducted in accordance with the protocol, all IC H and GCP regulations governing 
clinical study conduct , ethical principle s that have their origin in the Declaration of Helsinki, and 
all applicable local laws and regulations. The investigator must assure that the study is conducted 
in accordance with pre vailing local laws and customs.  
It is the investigator’s responsibility to ensure that this protocol is reviewed and approved by [CONTACT_3809] /EC. The IB must be provided to the IRB /EC. 
The IRB /EC must also review and approve th e site’s ICF  and any other written information 
provided to the subject and any advertisement that will be used for subject recruitment prior to its 
use. 
10.[ADDRESS_249922] Information and Consent  
Prior to screening for the study each patient and parent(s)/legal guardian /or LAR will be 
informed in detail about the study drugs to be administered and the nature of the clinical 
investigation with its risks and discomforts to be expected. The basic elements of informed 
consent as specified by [CONTACT_1622] (21 CFR 50.25) and ICH -GCP will b e followed.  
The investigator or his/her designee will explain the nature of all aspects of the study to the 
subject and/or their LAR, and answer all questions regarding this study, prior to obtaining 
informed consent.  
The investigator or his/her qualified  designee will obtain informed consent from each subject 
enrolled in the study, in accordance with the Declaration of Helsinki, the current version of the 
ICH guidelines and the local laws and applicable regulatory requirements.  
It is the responsibility of  the investigator to assure that the subject or LAR has consented and has 
signed the ICF before any activity or treatment is undertaken which is not part of routine care.  
The subject and/or LAR will receive a signed copy of the ICF and the original (digit al or 
hardcopy) will be retained in the site study records. The investigator or his/her designee will 
ensure documentation of the consent discussion in the subject’s medical record/source 
documents. The decision by [CONTACT_3184]/or LAR to participate in the study is entirely 
voluntary. The investigator or designate must emphasize to the subject and/or LAR  that consent CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249923]/Ethics Committee (IRB/EC) and use of the amended form (including 
ongoing subjects).  
10.[ADDRESS_249924] research organization (if 
applicable), the study monitor, employees of government a uthorities such as the  US FDA or 
other government authorities, and members of the IRB may inspect all documents and records 
required to be maintained by [CONTACT_093], including but not limited to, medical records 
(office, clinic, or hospi[INVESTIGATOR_307]) and pharm acy records for the subjects in this study. Each  clinical 
study site will permit access to such records.  
No information that would permit the identification of a specific individual will be provided for 
entry into the study database or study report. Study documentation submitted to the sponsor  will 
identify study participants by [CONTACT_209092].   
10.6 Study Monitoring  
The sponsor  and/or its designee are responsible for monitoring the study in accordance with the 
requirements of the ICH/GCP, and in accordance with written SOPs and the Clinical Monitoring 
Plan.  
The investigator will allocate adequate time for such monitoring activit ies. This monitoring will 
be in the form of on-site and/or remote  visits and other communication and will include review 
of original source documents, eCRFs, facilities and equipment, recruiting, record -keepi[INVESTIGATOR_007], 
protocol adherence, data collection, AE reporting, and other factors. The frequency of these 
visits will be reflected in the Clinical Monitoring Plan .  
The investigator will ensure that the monito r or other compliance or quality assurance reviewers 
are given access to all the above noted study -related documents and study related facilities (eg, 
pharmacy, diagnostic laboratory ), and has adequate space to conduct the monitoring visit.  If the 
monitori ng visit is being conducted remotely, adequate precautions are to be taken to ensure the 
confidentiality of all study related documents.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 59 of 82 
 
Confidential    
   
 10.7 Essential Documents Required Prior to Study Initiation  
Prior to the start of the study, Investigator's and study site compliance with all pre -investigational 
requirements will be evaluated and confirmed based on the site essential documents. The list 
may include:  
• Appropriate local health authority documentation properly signed and dated by [CONTACT_209093] (i.e. , the submission package);  
• Signed copy (original) of the approved protocol and Investigator’s Brochure;  
• Completed and signed statement of Investigator;  
• Signed Clinical Trial Agreement;  
• Curriculum vitae for the Investigator and sub -Investigators;  
• IRB/IEC na me and address; and membership list;  
• Letter of approval from the IRB/IEC for both protocol (identified by [CONTACT_209094]), informed consent form (identified by [CONTACT_141553]) and other study 
related patient materials;  
• Provisions for direct access to source/data documents if necessary for study -related 
monitoring, audits, IRB/IEC review and regulatory inspection.  
Upon satisfactory receipt of all required regulatory documents, Sponsor will arrange that IP be 
delivered to each study site . Supply of all other study materials will be the responsibility of 
OPKO Pharmaceuticals , LLC  and/or designee. Subject  entry should not begin until after the 
required regulatory documents are confirmed as received and the Initiation Meeting has 
occurred. A ll personnel expected to be involved in the conduct of the study will undergo 
orientation to include review of study protocol, instructions for eCRF completion, AE reporting 
and overall responsibilities including those for drug accountability and study fil e maintenance.  
The investigator and/or designee or  study monitor will prepare an investigator s ite file (ISF). 
This file should be used for all study related documents. The investigator will be responsible for 
keepi[INVESTIGATOR_209057]. The file will be 
inspected during monitoring visits.  
10.8 Investigator Site File (ISF)  
All documents required for the conduct of the study as specified in the ICH -GCP guidelines will 
be maintained by [CONTACT_209095]/or auditing by [CONTACT_16015], strategic partners and/or Regulatory 
Authorities.  
10.9 Case Report Forms and Study Records  
Data capture and management will be consistent with applicable ICH/GCP gui delines.  
All data collected during the study for subjects who are enrolled will be recorded in an 
individual, subject -specific eCRF  as part of an EDC system. The sponsor or designee will 
provide training to each investigative site on the EDC system and eCR Fs. All eCRFs will be 
completed in a timely manner  as data are available in the source for each subject. As EDC  will CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 60 of 82 
 
Confidential    
   
 be utilized, instructions, training records, and a log will be maintained to identify the designated 
site personnel who can enter data and/or sign off on an eCRF.  
A subject eCRF must be completed for each subject who signs a consent form  and undergoes any 
procedure related to the study . All data generated from external sources, (eg, central laboratory 
results ), will be integrated with the  subject eCRF data through programming or other data 
integration techniques.  
All eCRFs should be completed within [ADDRESS_249925]’s status throughout the course of the study in real time.  Queri es also should be 
resolved in a timely manner.  
The investigator will sign and date the indicated places on the eCRF via the EDC system’s 
electronic signature. These signatures will indicate that the investigator reviewed the data on the 
eCRF, the data queries, and the data clarifications and agrees with the content.  
10.[ADDRESS_249926] the integrity of the study.  
Major protocol deviations may include but are not limited to d eviations from the 
inclusion/exclusion criteria, informed consent deviations, concomitant medication restrictions, 
and any other protocol requirement that results in a significant added risk to the subject or has an 
impact on the quality of the data collec ted or the outcome of the study.  
Protocol deviations and associated handling of these will be described in a separate study plan.  
Protocol  deviations will be reported to the IRB  as per IRB post -approval reporting requirements .   
10.11  Data Generation and Analys is 
The investigators are responsible for the accuracy, completeness, and timeliness of the data 
reported on the eCRF. Study data management, monitoring, statistical analysis, and  reporting 
will be performed by  [CONTACT_209096]’s  SOPs.  
Com pleted eCRFs are required for each subject enrolled and signed an ICF .  Electronic data 
entry is accomplished through the 21CFR Part [ADDRESS_249927] parties, except for authorized business representatives or 
appropriate governmental health or regulatory authorities, without written permission of the 
sponsor .  
Data management, data analysis and prog ramming the submission -ready tables, listings and 
figures will be responsibility of the sponsor  and will be performed and managed per the 
sponsor’s  SOPs.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page 61 of 82 
 
Confidential    
   
 10.12  Retention of Data  
In compliance with the ICH/GCP guidelines, the investigator/institution will maintai n all eCRFs 
and all source documents that support the data collected from each subject, and all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial and as specified by [CONTACT_209097].  The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.  
Essential documents must be retained until at least two years after the last approval of a 
marketing application in an ICH region or a t least two years  have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_209098] s ponsor. It is the responsibility of the sponsor  to inform the 
investigator/institution as to when these documents no longer need to be retained.  
If the responsible investigator retires, relocates, or for other reasons withdraws from the study, 
the responsi bility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will 
accept the responsibility. The sponsor  or designee must be notified in writing of the name [CONTACT_73989]. Under no circumstances shall the investigator  relocate or dispose 
of any study documents before having obtained written approval from the sponsor.  
10.13  Financial Disclosure  
The principal investigator [INVESTIGATOR_149226] -investigators are required to provide certification 
(Financial Disclosure Form) that no financ ial arrangements with the sponsor  have been made 
where study outcome could affect compensation; that the investigator has no proprietary interest 
in the tested product; that the investigator does not have a significant equity interest in the 
sponsor ; and t hat the investigator has not received significant payments of other sorts. The 
investigator/sub -investigator is responsible for informing the sponsor  if these circumstances 
change during the course of the study or within one year of the end of his/her part icipation in the 
study.  
10.[ADDRESS_249928] be deleted prior to 
submission . 
10.15  Final Report  
A final study report will be developed at study closure. This report will comprise clinical and 
statistical integrated reports, according to the ICH E3 guidelines.  
  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249929]  
Adams JS, Liu PT, Chun R  et al. Vitamin D in defense of the human immune response. Ann 
N.Y. Acad Sci. 2007;1117:[ADDRESS_249930] infections: A 
systematic review and meta -analysis of randomized controlled Trials.  PLoS One . 
2013;8(6):e65835.  
Chun RF, Liu PT, Modlin RL et al. Impact of  vitamin D on immune function: L essons learned 
from genome -wide analysis. Front Physiol. 2014;5:151.  
Diao B, Wang C, Tan Y et al. Reduction and Functional Exhaustion of T Cells in Patients With 
Coronavirus Disease 2019 (COVID -19). Fron t Immunol. 2020;11:827  
Edfeldt K, Liu PT, Chun R et al. T -cell cytokines differen tially control human monocyte 
antimicrobial responses by [CONTACT_209099] D metabolism. Proc  Natl Acad Sci [LOCATION_003]. 
2010;107 :[ZIP_CODE] -8.  
Fabri M, Stenger S, Shin DM  et al.  Vitamin D is required for IFN -gamma -mediated 
antimicrobial activity of human macrophages . Sci Transl Med. 2011;3:104 ral102.  
Gombart AF, Saito T, Koeffler HP. Exaptation of an ancient Alu short interspersed element 
provides a highly conserved vitamin D -mediated innate immune response in humans and 
primates. BMC Genomics. 2009;10:321.  
Grant WB, Lahore H, McDonnell SL et al. Evidence that vitamin D supplementation could 
reduce risk of influenza and COVID -19 infections and deaths.  Nutrients 2020;12, 988; 
doi:10.3390/nu12040988.  
Holick MF, Binkley NC, Bischoff -Ferrari HA et al. Evaluation, trea tment, and prevention of 
vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 
2011;96:1911 –1930.  
Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J 
Clin Nutr .1995 ;61: 638S -645S . 
Jiménez -Sousa MÁ, Martínez I, Medrano LM et al. Vitamin D in human immunodeficiency 
virus infection: Influence on immunity and disease.  Front Immunol. 2018;9:458.  
Krutz ik SR, Hewison M, Liu PT et al.  IL-15 links TLR2/[ADDRESS_249931]. J Immunol. 2008;181 :7115 -20.  
Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, 
and phosphorus in patients with chronic kidney disease:  results of the study to evealutate early 
kidney disease.  Kidney Int. 2007;71:[ADDRESS_249932] activation pathways in 
human TLR2/1 -induced antimicrobial  responses. PloS one. 2009;4 :e5810.  
Liu PT, Stenger S, Li H et al. T oll-like receptor triggering of a vitamin D -mediated human 
antimicrobial r esponse. Science. 2006;311 :1770 -3.  CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceuticals, LLC  
CTAP101 (calcifediol) Extended -release Capsules  Page [ADDRESS_249933] infections: S ystematic review and meta -analysis of individual participant 
data.  BMJ. 2017;356:i6583.  
Montoya D, Inkeles MS, Liu PT et al. IL -[ADDRESS_249934] defense network in 
human tuberculo sis. Sci Transl Med. 2014;6 :250ra114.  
Nizet V, Ohtake T, Lauth X et al. Innate antimi crobial peptide protects the skin from invasive 
bacterial i nfection. Nature. 2001;414 :454-7.  
Powers JH, Guerrero ML, Leidy NK et al.  Development of the Flu -PRO: a patient -reported 
outcome (PRO) instrument to evaluate symptoms of influenza.  BMC Infectiou s Diseases 
2016;16 -1-11. 
Powers JH, Bacci ED, Guerrero ML et al. Reliability, validity, and responsiveness of influenza 
patient -reported outcome (FLU -PRO©) scores in influenza -positive patients.  Value in Health 
2018;21:210 -218. 
Rosen CJ, Adams JS, Bikle D D et al. The nonskeletal effects of vitamin D: An Endocrine  
Society scientific s tatement. Endocr Rev. 2012;33 :456- 92. 
Souberbielle J, Body J, Lappe JM et al. Vitamin D and musculoskeletal health, cardiovascular 
disease, autoimmunity and cancer: Recommenda tions for clinical practice. Autoimmun Rev . 
2010; 9:709-715. 
Sprague, SM, Silva, AL, Al -Saghir, F, et al.  Modified -Release Calcifediol Effectively Contarols 
Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney 
Disease.  Amer J of Nephrology 2014: 40:435 -545; DOI: 10.1159/[ADDRESS_249935], PW, Melnick, JZ, et al.  Use of Extended -Release Calcifediol to Treat 
Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.  Amer J of 
Nephrology 2016: 4 4:316 -325; DOI: 10.1159/000450766  
Srikanth P, Chun RF, Hewison M et al. Osteoporotic Fractures in Men Study Research G. 
Associations of total and free 25OHD and 1,25(OH)2D with serum markers of inflammation in 
older men. Osteoporos Int. 2016; 27:2291 -300.  
Strugnell SA, Sprague SM, Ashfa q A et al. Rationale for raising current clinical practice 
guideline target for serum 25 -hydroxyvitamin D in chronic kidney disease.  Am J Nephrol . 
2019;49:284 -293. 
 
 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 67 of 82 
 
Confidential    
   
 APPENDIX  2. PACKAGE INSERT FOR  RAYALDEE® (REV. APRIL  2021) 
 
 
  
   
    
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 68 of 82 
 
Confidential    
   
    
 
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 69 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 70 of 82 
 
Confidential    
   
  
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 71 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 72 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 73 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 74 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 75 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 76 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 77 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 78 of 82 
 
Confidential    
   
  
CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021
  
Protocol CTAP101 -CL-2014  OPKO Pharmaceutcials, LLC  
CTAP101 (calcifediol) Extended -release Capsules   Page 82 of 82 
 
Confidential    
   
 APPENDIX  4. INVESTIGATOR SIGNATURE  
[CONTACT_2759]:  A Randomized, Double -Blind Placebo -Controlled Study to Evaluate 
the Safety and  Efficacy of Rayaldee (calcifediol) Extended -relea se 
Capsules to Treat Symptomatic Patients Infected with SARS -CoV -2 
(REsCue ) 
Study Number:  CTAP101 -CL-2014  
Final Date:  12 November  2021 
I agree:  
To assume responsibility for the proper conduct of the study at this site.  
To conduct the study in compliance with this protocol, with any future amendments, and with any other 
written study conduct procedures provided and reviewed and approved by [CONTACT_209100], LLC 
or its designee(s).  
Not to implement any deviations from or changes to the protocol without agreement from the sponsor and 
prior review and the written approval from IRB/EC, except where necessary to eliminate an immediate 
hazard to the subjects, or for administrative aspects of the study (where permitted by [CONTACT_209101]).  
That I am thoroughly familiar with the appropriate use of the investigational drugs, as described in this 
protocol, and any other information provided by [CONTACT_72017], but not limited to, the following: 
the cu rrent Investigator’s Brochure (IB) or equivalent document provided by [CONTACT_209100], 
LLC or its designee(s).  
To ensure that all persons assisting me with the study are adequately informed about the investigational 
drugs and of their study -related du ties and functions as described in the protocol.  
That I have been informed that certain regulatory authorities require the sponsor to obtain and supply 
details about the investigator's ownership interest in the sponsor or the study drug, and more generally  
about his/her financial ties with the sponsor. OPKO Pharmaceuticals, LLC will use and disclose the 
information solely for the purpose of complying with regulatory requirements.  
Hence, I:  
• Agree to supply OPKO Pharmaceuticals, LLC with any information regar ding ownership interest and 
financial ties (including those of my spouse and dependent children).  
• Agree to update this information if any relevant changes occur during the course of the study and for 
one year following completion of the study.  
• Agree that O PKO Pharmaceuticals, LLC may disclose this information about such ownership 
interests and financial ties to regulatory authorities.  
Signed:    Date:    
 
Printed Name:_______________________________________  
 CTAP101 | CTAP101-CL-2014 | CTAP101-CL-2014 Protocol
VV-TMF-183735 | Version 8.0 dated 16 Nov 2021